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By Ruiqi Huang 
 




Solid tumors possess biological features that are different from those in healthy tissues, 
which provides opportunities of anticancer treatment by nanomedicines.  Due to the presence of 
the fenestrated tumor vasculatures, nanomedicines can selectively accumulate in tumor tissues by 
the enhanced permeability and retention (EPR) effect.  The acidic pH in tumor interstitium (pH 
6.0-7.0) also provides a promising mechanism to trigger the nanomedicines to promote the 
cellular uptake of cargo drugs.  The previously reported stealth liposomes coated with PEG are 
known to accumulate in tumors owing to their prolonged circulation time.  The PEG coating on 
liposomes can hinder serum protein adsorption and thus prevent rapid elimination by the 
reticuloendothelial system, thus increasing the liposome circulation time. However, liposomal 
interaction with cancer cells can also be hindered by the PEG coating.   
In order to improve the anticancer activity of stealth liposomes, novel synthetic 
imidazole-based lipids were introduced to the composition of stealth liposomes to develop the 
pH-sensitive imidazole-based convertible liposomes (ICL).  At acidic pH, the imidazole-based 
lipids would protonate to acquire positive charges, thus clustering with the negatively charged 
PEGylated lipids.  Such lipid-lipid electrostatic interaction would induce phase separation of the 
bilayer to generate a PEG-free domain that displays excess positive charges.  Such newly 





with negatively charged cancer cells and/or enhanced drug release, therefore overcoming the 
drawback of traditional stealth liposomes.  
After synthesizing the imidazole-based lipids DHI, DHMI and DHDMI, we constructed 
doxorubicin (DOX)-loaded ICL formulations.  The physicochemical properties of ICL were 
characterized, and factors influencing such properties were explored.  The pH-triggered 
acquisition of positive charges of ICL was confirmed by the elevation of ζ- potentials and 
aggregation with negatively charged model liposomes that mimic bio-membranes at acidic pH 
6.0-7.0.  Acidic pH-triggered release of ICL was confirmed by drug release assays.  It was also 
found that although the incorporation of cholesterol can remarkably reduce the size and increase 
the encapsulation efficiency (EE) of ICL, it also hinders the pH-sensitivity of ICL.  The 
morphology of ICL at both pH 7.4 and pH 6.0 was characterized under transmission electron 
microscopy (TEM), which showed morphological changes in response to acidic pH 6.0, which 
further supported the proposed pH-sensitivity of ICL.   
Cytotoxicity assays on 3D MCS of HeLa, A549, MDA-MB-231 and MDA-MB-468 cell 
lines were conducted to evaluate the anticancer activity of ICL formulations.  ICL formulations 
without cholesterol showed considerably enhanced anticancer activities against MCS compared 
with the non-sensitive stealth liposomes (NSL).  However, incorporation of cholesterol decreased 
such activities.  The IC50 values of cholesterol-free ICL and ICL with cholesterol against MCS 
strongly suggested that the pH-sensitivity introduced by the imidazole-based lipids would 
enhance the anticancer activity of stealth liposomes, while the hindrance of the pH-sensitivity by 
cholesterol would reduce such  activities.   
Taken together, ICL’s pH-sensitivity is correlated with their enhanced anticancer activity 
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CHAPTER 1:  INTRODUCTION 
 
1.1 Cancer and Solid Tumor 
1.1.1 Introduction on cancer.  Cancer is a generic term of a group of diseases that 
involves abnormal growth, migration, and invasion of cells [1].  Mostly, cancer is known as 
malignant tumors with the potential to invade to other parts of the body, which are in contrast to 
benign tumors that do not spread.  Cancer is the second leading cause of death globally, and over 
100 types of cancers have been found [2].  Five  to ten percent of cancers are caused by genetic 
hereditary while vast majority of cancer are induced by external factors including tobacco use, 
obesity, lack of physical activity, excessive drinking of alcohol, and infections such as 
Helicobacter pylori, hepatitis and HIV [3].  Cancers show symptoms such as lumps, abnormal 
bleeding, weight loss, and can be diagnosed by screening tests, medical imaging, and biopsy [4].  
Cancer is typically treated with combination of radiation therapy, chemotherapy, targeted therapy 
and surgery.   
1.1.2 Biological features of solid tumors.  Neoplasm, also named solid tumors, is a type 
of abnormal and excessive growth of tissue in body, which can be classified into benign tumors, 
potential malignant tumors and malignant tumors. Malignant tumors will be the only type of 
solid tumors for discussion in this thesis.   
The physiology of solid tumors differs from that of normal tissues in a variety of aspects.  
Most of the biological features of solid tumors originate from the difference of vasculatures 
between normal and tumor tissues [5].  In contrast to the healthy, orderly vasculature of normal 
tissues, tumor blood vessels have more distended shape, more leaky walls and more sluggish 





order to maintain the basic supply of oxygen and nutrients.  However, those blood vessels are 
usually poorly formed, which leads to several biological features in solid tumors, including 
hypoxia, necrosis, acidic microenvironment, unique extracellular matrix (ECM), and drug 
resistance.   
1.1.2.1 Hypoxia in solid tumors.  The metabolic hypoxia in solid tumors is a 
pathophysiological consequence of the disturbed vasculature and the deterioration of diffusion 
conditions [6].  When a tumor’s oxygen supply is not restricted, its oxygen consumption rate and 
adenosine triphosphate (ATP) production is comparable with those in normal tissues.  However, 
as the tumor grows larger, regions that lack microcirculation cannot obtain adequate supply of 
oxygen from blood vessels.  Such regions enter a condition of hypoxia, which features 
progressive decrease of oxygen partial pressure and cellular ATP production.  Hypoxia in tumors 
is largely associated with tumor propagation, malignant progression and resistance to therapy.  
Therefore, hypoxia has become a major issue in cancer treatment [6].  Hypoxia induces proteome 
changes in cancer cells and stromal cells in tumors, which in turn causes cellular quiescence, 
differentiation, apoptosis, and necrosis [7].  Evidence is accumulating that hypoxia in solid 
tumors drives malignant progression of cancer cells, which is marked by increasing probability 
of metastasis and increasing resistance against nonsurgical therapy (e.g. radiotherapy and 
chemotherapy) concomitant with tumor growth [8, 9].   
1.1.2.2 Necrosis in solid tumors.  Necrosis occurs in most solid tumors. The edges of 
necrotic regions in tumors were found to be parallel to the neighboring blood vessels, suggesting 
that the necrosis is caused by limited diffusion of adequate oxygen and nutrients into cancer cells 
as well as limited transfer of metabolites from cancer cells to the blood vessels [10].  A relatively 





μm, was observed in tumors, which is consistent with the estimated distance of sufficient oxygen 
diffusion in tissues [11].  Such in-between areas contain cells that are still viable but with very 
low level of oxygen.  This type of quiescent cells, together with the necrotic cells farther away 
from the blood vessels and the proliferative cells closer to the blood vessels, constitute the highly 
heterogeneous tumor tissues.  
1.1.2.3 pH gradients in solid tumors.  Acidic pH is a major feature of tumor tissues and 
is typically represented by two pH gradients in solid tumors: the reversed gradient between pHi 
and pHe, and the pH gradient between the outer and center region of tumors.  Normal cells in 
healthy tissues have an intracellular pH (pHi) of 7.2 and a slightly higher extracellular pH (pHe) 
of 7.4.  In contrast, cancer cells in tumor tissues are characterized by a relatively higher pHi of 
7.2 and a lower pHe of 6.0-7.0 [12].  This “reversed” pH gradient in tumors not only provides 
essential support for the growth, invasion and migration of tumors, but also helps protect the 
tumors from anti-tumor immunity and apoptosis [13].  The pHe of cancer cells also varies in 
different regions of solid tumors.  The pH in the outer proliferative and quiescent areas average 
around pH 7.0, while the pH in the tumor cores generally drops to 6.1-6.4[14, 15].  
The acidic pH in solid tumors results from the accumulation of the metabolic by-product 
of hypoxia – lactate.  Under the condition of low oxygen and nutrient concentrations, cancer 
cells tend to produce lactate from the anaerobic glycolytic pathway more than oxidative 
phosphorylation for energy production [16].  In consequence, lactate accumulates in the tumor 
interstitium, especially in the tumor core where the oxygen penetration and waste removal are 
extremely restricted.  The accumulation of the acidic lactate contributes to decrease of pH in 
tumor interstitium, leading to drug resistance [17].  Therefore, it has been considered a potential 





1.1.2.4 Extracellular matrix (ECM) in solid tumors.  Extracellular matrix (ECM), a 
highly dynamic structure, is the major structural component in tumor microenvironment.  The 
ECM of cancer cells provides both biochemical and physical support for the solid tumor, and is 
distinct in its composition and stiffness compared with normal ECM [19].  The dynamics of 
ECM in solid tumors becomes abnormal due to the disruption of equilibrium between the 
synthesis and secretion of ECM components and the expression of matrix-remodeling enzymes.  
The ECM in tumors contains a variety of proteins, including fibrous protein, glycoproteins, 
proteoglycans, and polysaccharides.  The fibrous ECM proteins, such as collagen, partake in 
tumor tissue development by providing mechanical strength, altering cell adhesion, and 
promoting cell migration [20].  Glycoproteins in tumors make the ECM a cohesive network to 
link cells together with structural components, such as fibulin, fibrillin, and laminin.  
Proteoglycans play a crucial role in ECM assembly and cell signaling by binding with growth 
factors and acting as co-receptors of ligands.  Polysaccharides, such as hyaluronic acid (HA), 
play a role in filling the interstitial space and buffering physical stress on the ECM.  In addition 
to the biochemical effects, the tumor ECM also provides a physical barrier that hinders the 
transport of water, solutes and chemotherapeutics [21].  Due to the overexpression of many ECM 
components, tumor ECM is typically stiffer than ECM in healthy tissues.   
1.1.2.5 Opportunities provided by biological features of solid tumors.  Conversely, the 
aforementioned biological features of solid tumors, such as deformed vasculature, hypoxia and 
physical barriers from ECM also provide opportunities of anticancer treatment.  For example, 
Tirapazamine (TPZ), can be activated by the hypoxia to selectively kill cancer cells in solid 
tumors [5].  Nanomedicines can diffuse across the more porous tumoral blood vessels to 





drug release from pH-sensitive drug delivery systems [23].  Some gene therapeutics have been 
developed to be activated by hypoxia or necrosis of solid tumors [24, 25].   
1.2 Anticancer Drugs 
1.2.1 Introduction on anticancer drugs.  Generally, anticancer drugs are classified 
according to their mechanism of action.  Major groups of anticancer drugs include cytotoxic 
drugs, hormonal drugs and targeted drugs.  Correspondingly, three major modalities are included 
in cancer pharmacotherapy.  The cytotoxic chemotherapy connotes the use of non-specific 
cytotoxic drugs to suppress cancer cell mitosis and division, but excludes therapeutic agents that 
are more targeted or block extracellular signals [26].  Therapies that inhibit tumor growth signals 
from endocrine hormones are called hormonal therapies, which are specifically applied in 
treatments of breast cancer and prostate cancer [27].  Therapies that inhibit tumor growth signals 
associated with specific targeted receptors are referred as targeted therapies [28].  Because 
anticancer drugs are administrated into the blood circulation, they represent a type of systemic 
therapy and could address cancer at any location in the body.  Such systemic anticancer therapy 
is usually in conjunction with local anticancer therapy, such as radiation therapy, surgery, and 
hyperthermia therapy, which exert anticancer effects only where they are applied [29].   
1.2.2 Challenges and limitations of cytotoxic chemotherapies.  Chemotherapy, usually 
referred as chemo or CTX, is a type of cancer treatment that uses single or multiple cytotoxic 
drugs.  Closely correlated to medical oncology, chemotherapy is one of the major categories of 
pharmacotherapy for cancers [30].  Conventional chemotherapeutic agents inflict toxicity to cells 
and interfere with their mitosis.  The cytotoxic drugs in conventional chemotherapy are classified 
to antimetabolites (e.g. Methotrexate and Gemcitabine), alkylating agents (e.g. Cisplatin and 





inhibitors (e.g. Etoposide and Topotecan), antibiotics (e.g. Doxorubicin and Bleomycin) and 
other miscellaneous agents (e.g. Tretinoin and Hydroxyurea).  In general, chemotherapy using a 
combination of cytotoxic drugs  have shown better efficacy than a single cytotoxic drug [31].   
Poor selectivity is the major drawback of chemotherapy. Because cancer cells originate 
from normal cells, anticancer drugs that inhibit the growth of cancer cells are also cytotoxic to 
normal cells.  Many of the side effects of chemotherapy are attributed to the damage of normal 
cells that are sensitive to anti-mitotic drugs, including those in digestive tract, bone marrow and 
hair follicles [32].  Therefore, common side effects of chemotherapy include decreased 
production of blood cells, mucositis in gastrointestinal tract and hair loss. For example, 
cyclophosphamide and methotrexate, which are commonly used agents for breast cancer are 
known to cause neutropenia, alopecia and emesis [33].  Moreover, cisplatin is widely known to 
have nephrotoxicity due to accumulation of transported cisplatin in the kidney [34], and 
doxorubicin has been known to have cardiotoxicity, which may induce arrhythmias, pericarditis, 
myocarditis and acute heart failure [35].   
Besides poor selectivity, chemotherapy is also limited by drug resistance, which is a 
major cause of failure of chemotherapeutic drugs.  One cause of drug resistance is that cancer 
cells overexpress transporters that that protect them from chemotherapeutics [36].  The 
transporters (e.g. p-glycoprotein) can be overexpressed on cancer cell surface to move drugs 
from cytosol to the interstitium.  Agents that inhibit the transporters have been developed, but not 
yet approved for clinical use due to toxicity [37].  Another cause of drug resistance is gene 
amplification that induces multiple copies of a cancer cell, which is against the effect of 
chemotherapeutics on the gene expression in cell proliferation [36].  Furthermore, the cellular 





when exposed to chemotherapeutics.  Additionally, the DNA damage exerted by chemotherapy 
agents can be repaired by enzymes in some cancer cells [38].  Besides resistance against a single 
drug, cancer cells may also develop resistance against a group of drugs with similar mechanism 
and cross-resistance against several drugs of different targets and mechanisms [39].   
Chemotherapy is also facing challenges in effective drug distribution and penetration due to the 
deformed vessels in tumors.  New blood vessels are formed in tumors as they grow larger, but 
such tumoral blood vessels have poor structure and are only distributed in the peripheral region 
of a solid tumor.  Therefore, the core of a solid tumor usually has inadequate blood supply, and 
consequently poor drug distribution[40].   
1.2.3 Targeted anticancer drug delivery.  Targeted drug delivery, also known as smart 
drug delivery, is a method that delivers drug(s) to a patient at higher concentration  at the 
targeted site of action [41].  Targeted drug delivery systems aim to have prolonged and localized 
drug interaction with the diseased tissue to improve the efficacy.  Moreover, targeted drug 
delivery aims to decrease the side effects of cytotoxic chemotherapy by decreasing the 
concentration of the cytotoxic anticancer drug in  healthy tissues [42].  Targeted drug delivery 
systems have strong market prospects, because the reduced toxicity means significantly 
improved survival and life quality for cancer patients.  The drawback of targeted delivery 
systems is the higher cost that makes production and dosage modification more challenging.  
Targeted drug delivery has been closely associated with the development of nanomedicines.  
Generally, the strategies of drug targeting in such drug delivery systems can be classified into 
passive targeting and active targeting [42, 43].   
1.2.3.1 Passive targeting.  Passive targeting, also known as physical targeting, increases 





delivery system [45].  The passive targeting for cancer treatment is directly related to the 
circulatory system and is assisted by the enhanced permeation and retention (EPR) effect.  
Translocation of molecules through vascular interspace is closely dependent on the sizes of 
molecules and the vasculature morphology.  The short half-life of conventional 
chemotherapeutics in blood circulation and their indiscriminate accumulation in healthy tissues 
are attributed to their small size (generally < 1000 Da), which lead to extravasation through 
vascular pores in healthy tissues (50-150 nm) [44].  This mode of biodistribution constitutes poor 
selectivity and thus high general toxicity of conventional, small molecule chemotherapy agents.  
In comparison, blood vessels in tumors carry pores in the size range  of 200-1200 nm [45], 
resulting in enhanced vascular permeability and lowered clearance of nanomedicines in the size 
range of 100-200 nm.  Therefore, the fenestrated neovascular wall in tumors elicits selective 
accumulation of nanomedicines but not small molecular drugs (Figure 1.1).  However, extended 
half-life of a nano drug delivery system in blood circulation is necessary for its passive targeting 
into tumors.  In order to achieve the prolonged circulation in blood, a nano drug delivery system 
is often coated with hydrophilic  polymers, such as polyethylene glycol (PEG) to hinder its 






















 (Figure 1.1 Continued) 
 
Figure 1.1. Conventional low molecular weight (MW) drugs versus nanomedicines: low MW 
drugs showed high accumulation in both healthy tissues (upper to the vessel, pink) and tumor 
tissues (lower to the vessel, dark red), while nanomedicines showed specific promoted 
accumulation in tumor tissues.  [47] 
 
Passive targeting provides great advantage in nanomedicine therapy but it also faces 
several challenges.  One challenge for the EPR effect is the vascular features in tumors.  The 
vascular density varies in different types of cancers. Specifically, it was found hepatic and renal 
carcinoma had stronger EPR effect than pancreatic and prostate cancers [47].  Moreover, the 
vessel distribution within a tumor is heterogeneous.  It was reported that drug distribution is 
limited in the central necrotic regions in tumors, which are far from the blood vessels and 
therefore little impacted by EPR effect, which relies on vascular permeability [48].  Another 
challenge for the EPR effect is the stromal compartment in tumors, which is composed of ECM 
and stromal cells.  The ECM components, such as collagen and hyaluronic, form a dense barrier 
against the penetration of nanomedicines from blood vessels to tumor interstitium [49].  Several 
studies have confirmed that nanomedicine accumulation is compromised in collagen-rich tumors, 
as the composition and distribution of collagen in tumors causes heterogenous distribution of 

















1.2.3.2 Active targeting.  Active targeting takes effect based on the phenotypic and 
biochemical characteristics in diseased tissues.  In addition to passive targeting, active targeting 
would help drug delivery systems take effect more specifically at targeted sites and spare healthy 
tissues [51].  Active targeting can be accomplished using several approaches, which are divided 
into ligand-receptor binding, activated targeting, and locally activated targeting.   
The most common active targeting strategy is ligand-receptor binding, which employs 
biological interactions between ligand and its receptor [52].  Drug delivery systems containing 
specific ligands would selectively bind with their coupling receptors, which are overexpressed on 
the surface of tumor cells but not normal cells, in order to localize the payload drug to tumor 
tissues [53].  It was reported the ligand-receptor binding may trigger endocytosis and cellular 
drug uptake, which helps suppress the multidrug resistance of tumor [54].  For example, 
transferrin has been utilized to mediate endocytosis by conjugating with nano-formulations and 
then interacting with receptors on cell membranes.  The transferrin-conjugated nano-
formulations showed better cellular uptake than the non-conjugated counterparts [54].  One of 
the major challenges for the ligand-receptor mediated active targeting is the limited selectivity.  
Firstly, selectivity of such active targeting is compromised by the heterogeneity of receptor 
expression by cancer cells.  Different receptors are expressed in various types of cancers; 
receptors are expressed differently in the same tumor at different developmental stages; cultured 
cancer cells in vitro may not express the same receptors as in vivo tumor cells – all these means 
that heterogeneity leads to imprecise evaluation of drug delivery systems [55].  Secondly, 
selectivity also relies on receptor density on cancer cells. Such active targeting would only take 
effect where the receptor is considerably over expressed by cancer cells than normal cells [55].  





both the distance and the affinity between a ligand and its receptor.  The binding would occur 
only when the distance between the ligand and the receptor is smaller than 0.5 nm, beyond which 
the delivery system would not accumulate at the targeted site [56].  Moreover, excessive binding 
between the ligand and the receptor may generate a binding-site barrier, which would hinder the 
uptake of therapy agents by tumors [32].   
One strategy to achieve active targeting is called locally activated drug delivery, which 
initiate the formulation-cell interaction and the drug release by signals that are specific to the 
diseased site such as pH, or by external stimuli such as temperature, ultrasound, light and 
magnetic field [57, 58].  This type of delivery systems is also known as stimulus-sensitive 
systems. Some locally active drug delivery systems are sensitive to specific signals generated by 
the abnormal biochemical properties of tumors, such as the acidic microenvironment and the 
lower redox potential due to hypoxia [59, 60].  Some locally active drug delivery systems can 
achieve enhanced release in response to external stimuli, such as ultrasound, light, magnetic field 
and electric field [61-64].   
1.2.4 Anticancer nanomedicines.  Nanomedicine, also named nanotherapeutic, is 
defined as the application of nanomaterials and nanotechnology for medical purposes [65].  
Nanomedicine represents an emergent field address issues of conventional anticancer drugs.  
Designs of nano-drug delivery systems aim to maximize bioavailability both at specific sites and 
over a desirable period of time.  Loading therapeutic agents into lipid- or polymer-based 
nanoparticles can help improve the pharmacokinetics of therapeutics, such as reduced 
distribution volume, lowered clearance rate and longer circulation time [65].  Targeted 
nanomedicines have lowered overall drug consumption and decreased toxicity by accumulating 





Nanomedicines have also been applied to improve anticancer immunotherapy by delivering 
specific tumor microenvironment (TME)-normalizing agents [67].  Nano-formulations can also 
deliver multiple drugs to counterdrug resistance and to achieve synergistic therapeutic effects 
[68].  Application of amphiphilic materials such as phospholipids in nano-formulations, helped 
enhance the solubility, stability and bioavailability of lipophilic drugs in blood circulation [69].  
Furthermore, the 10-200 nm size range of nanomedicines significantly benefits their drug 
delivery.  Compared with small molecule therapeutics, the larger surface area of nanomedicines 
improve their interaction with biological membranes [70]; compared with larger delivery systems 
such as microspheres and microcapsules, nanomedicines are less invasive and have shorter 
biochemical reaction time [71].   
Nanomedicines are classified into lipid nanosystems, polymeric NPs, engineered NPs, 
dendrimers, nanotubes, fullerenes, quantum dots, and viral vectors. Among them, lipid 
nanosystems include liposomes, solid lipid nanoparticles (SLNs), lipid-based micelles, emulsions 
and lectin-modified SLNs [72].  Ideal nanocarriers of therapy agents are expected to possess high 
bio-capacity, low toxicity and low immunogenicity.  However, the toxicity of nanocarriers 
themselves, namely nanotoxicity, has recently become a concern for their medical applications 
[73, 74].  Investigations on limitations of nanomaterials are still ongoing in order to broaden their 
applications in health sciences.   
1.2.5 Doxorubicin (DOX) and DOX-loaded Nano-formulations.  Doxorubicin (DOX 
or DXR) (Figure 1.2), with the brand name Adriamycin, was approved in U.S. in 1974. DOX is 
administrated by intravenous (IV) injection to treat a wide range of cancers, including breast 
cancer, ovarian cancer, bladder cancer, lymphoma, Kaposi’s sarcoma, and acute lymphocytic 





Streptomyces bacterium, and is one of the most effective anticancer medications [76].  DOX is a 
fluorescent molecule with a maximum excitation wavelength at ~485 nm and emission between 
560-590 nm.  The broad spectrum of anticancer activity and the fluorescence makes DOX one of 
the most commonly used payload drugs in the development of anticancer drug delivery systems.  
Cytotoxicity of DOX is based on two different mechanisms.  Firstly, DOX intercalates into DNA 
to inhibit the function of topoisomerase II (TOP II), which induces DNA breakage and cell death.  
Furthermore, DOX is also known to generate free radicals that damage cell membranes, DNA, 
and proteins, which is another mechanism to induce cell death [77].   
 
 
Figure 1.2.  Chemical structure of DOX.  
 
Common side effects of DOX include hair loss, nausea and vomiting, diarrhea, missed 
menstrual periods, loss of appetite, weakness, tiredness, and reddish color in urine, tears and 
sweat [75].  Moreover, DOX is known to cause severer and possibly life-threatening 
cardiotoxicity.  To mitigate the dose-limiting side effects, DOX-loaded nanomedicines have been 
developed, including Doxil®, Myocet™, ThermoDox®, LipoDox®, and Caelix® [78-80]. 
Doxil, the DOX-encapsulated long-circulating stealth liposomes, was the first nano-sized 
C27H29NO11 
Exact Mass: 543.17 
Mol. Wt.: 543.52 
m/e: 543.17 (100.0%), 544.18 (30.9%), 545.18 (6.8%), 546.18 (1.1%) 





liposomal product to obtain regulatory approval [79].  It was approved in the U.S. in 1995 for the 
treatment of ovarian cancer and AIDS-related Kaposi’s sarcoma. The mean diameter of Doxil 
liposomes is 80-90 nm and each lipid vesicle can encapsulate up to 15000 DOX molecules [81].  
Many studies have demonstrated that, compared with free DOX, Doxil has a drastically lower 
cardiotoxicity and substantially higher efficacy, both owing to its preferred accumulation at 
tumor sites [82, 83].  Owing to the nanometer size, Doxil can accumulate at tumor sites based on 
the mechanisms of passive targeting (1.2.3.1).  The PEG coating of Doxil hinders its recognition 
by the RES system (1.3.4.2), thereby increasing its circulation time to consolidate the passive 
targeting.   
1.3 Liposomes   
1.3.1 Introduction of liposomes.  As one of the nanocarriers, liposome is a type of nano-
scaled spherical vesicles which consist of a lipid bilayer shell and an aqueous interior.  The 
bilayer structure is attributed to the special properties of lipids. Most liposomes are composed of 
phospholipids, which are amphiphilic molecules carrying a hydrophilic head consisting of a 
phosphate group and a lipophilic tail consisting of two fatty acid chains.  When phospholipids 
are dispersed in water, they spontaneously form enclosed bilayer structures.  The amphiphilicity 
of phospholipids makes liposome a versatile carrier for both hydrophilic and hydrophobic drugs.  
Composition of liposomes may also include other lipids such as cholesterol, as long as they are 
compatible with the lipid bilayer [84].  There are currently more than ten clinically used 
liposome-based products and hundreds of new liposome formulations in clinical trials. So far 
liposomal formulations of anticancer and antifungal agents have been commercialized [85].   
1.3.2 Preparation of liposomes.  Liposomes can be prepared by several types of 





which a dry film of lipids is prepared and then hydrated in an aqueous medium [78].  Ethanol 
injection method is commonly used in industrial manufacturing of liposomes, in which an 
ethanol solution of lipids is rapidly injected into an aqueous medium through a needle to disperse 
the lipids and promote the vesicle formation [78].  Other methods include reverse-phase 
evaporation and freeze-drying [79].  Techniques such as freeze-anneal-thawing, membrane 
extrusion, sonication and homogenization are applied to control the size and size distribution of 
liposomes [78].   
In preparation of drug-loaded liposomes (Figure 1.3), hydrophobic drugs can be mixed 
with the compositional lipids in the thin film to incorporate into the lipid bilayer during film 
hydration/ethanol injection, while hydrophilic drugs can be encapsulated either passively by 
using an aqueous drug solution for film hydration/ethanol injection or actively by remote loading 
with an ion gradient.  Many liposome formulations encapsulate DOX by the remote loading 
method [81].  Remote loading, also known as active loading, efficiently drives DOX molecules 
into the liposomes by a transmembrane ion gradient from a highly concentrated salt solution in 
the aqueous interior of liposomes.  Traditionally, DOX is loaded by a pH gradient established by 
a concentrated ammonium sulfate solution in the aqueous liposome interior (Figure 1.4), which 
maintained the pH at pH 4-5.  The remote loading occurs when DOX molecules diffuse from the 
bulk media to the liposome aqueous interior, where they are protonated at the acidic pH and then 
form a sulfate salt precipitate, which enables high drug loading and stable drug retention [85].  
This remote loading driven by ammonium sulfate is less effective when the intraliposomal pH is 
neutral or slightly basic.  As improved alternatives, metal salts such as manganese sulfate and 
copper gluconate have been reported to achieve high loading efficiency at pH > 6.5 [86, 87] by 







Figure 1.3.  Schematic of preparation methods of drug-loaded liposomes. (a) Hydrophobic drug-
loaded liposomes with film hydration method. (b) Hydrophobic drug-loaded liposomes with 
ethanol injection method. (c) Hydrophilic drug-loaded liposomes with film hydration method. (b) 




Figure 1.4.  Remote loading of DOX into liposomes by ammonium sulfate gradient. (a) Reactions 
occurring inside and outside of the vesicles which caused (DOX-NH3)4SO4 precipitate. (b) Spatial 
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1.3.3 Advantages of liposomal drug delivery systems.  The liposomal drug delivery 
system was first proposed in 1961, and now has shown many applications in delivery of small 
molecule drugs, biomolecules and genes [87].  Liposomes are the most commonly utilized 
nanocarriers for targeted drug delivery due to a number of  advantages [88].  Firstly, liposomes 
are able to carry a variety of cargo molecules, including small molecules, proteins, nucleotides 
and plasmids [85].  Specifically, liposome can encapsulate hydrophilic molecules in the aqueous 
interior, incorporate hydrophobic molecules in cavities of fatty acid chains, and carry drugs 
conjugated on the surface (Figure 1.5).  Secondly, because both external and internal surfaces of 
the bilayer are outlined by the hydrophilic headgroups of phospholipids, liposomes represent a 
colloidal system to stabilize diverse payload molecules in aqueous media.  Encapsulated 
hydrophilic payload molecules can be protected by the lipidic bilayer from deactivation in 
physiological media.  Hydrophobic molecules that are incorporated in the liposome membrane 
can improve the solubility, stability and bioavailability in blood circulation [69, 89].  Thirdly, due 
to their generally biocompatible components, liposomes tend not to inflict severe 
immunoreaction or toxicity [90].   
 
 













1.3.4 Liposomal drug delivery and drug release.  The pharmacokinetic profile and 
efficacy of liposomal drug delivery systems are largely correlated to: a) physicochemical 
characteristics including size, surface charge, steric hindrance, stability, and drug loading 
efficiency, b) successful delivery of drugs to the targeted sites, and c) successful release of drugs.  
Complex mechanisms have been developed to improve the precision of liposomal drug delivery 
and drug release, which can occur both extracellularly and intracellularly.  The extracellular 
delivery by liposomes include passive targeting and active targeting (1.1.2.2).  The liposomes are 
circulated in blood and then extravasate to accumulate in the interstitium of diseased tissues, 
followed by either drug release or endocytosis.  Liposomes are often designed to release the 
payload more quickly in response to specific signals at the target site (aka triggered release), 
such as the acidic pHe in tumors.  The intracellular delivery of liposomes is needed for protein 
and nucleic acid therapeutics, because those molecules need to reach appropriate subcellular 
organelles to exert activity but cannot cross cell membranes by diffusion due to their large size 
and high hydrophilicity [91].  One of the major mechanisms of delivering large molecules into 
cells is endocytosis, the means of which include clathrinmediated endocytosis, phagocytosis, 
micropinocytosis and caveolae-mediated endocytosis.  Endocytosis provides a mechanism to 
cross the plasma membrane but can result in varying levels of lysosomal degradation and 
exocytosis [92].  In order to avert these processes, some liposomal systems are designed to 
escape the endosome in response to a local stimuli such as acidic pH and enzymatic activities in 
the endosome [93, 94].  Besides endocytosis, lipid-mediated fusion with cell membrane is 
another major pathway for liposomes to release drugs into cells [95, 96].  
1.3.5 Classification of liposomes.  Liposomes can be formulated and processed to differ 





can be grafted on the surface of liposomes to cater to various applications in drug delivery 
(Figure 1.6).  Major classes of liposomes are summarized in Table 1.1.   
 
Table 1.1 







Small Unilamellar Vesicles (SUV) 
With a single bilayer. Size ranges from 
20 to 100 nm 
Large Unilamellar Vesicles (LUV) 
With a single bilayer. Size ranges from 
100 to 1000 nm 




Simply contain neutral/anionic 
phospholipids and cholesterol 
Cationic Liposomes Contain cationic lipids such as DOTAP 
Application 
Stealth Liposomes 
Contain a PEG coating to improve 
circulation time 
Stimulus-sensitive Liposomes 
Physicochemical changes in response to 
specific stimuli 
Ligand Targeted Liposomes  
Grafted with targeting ligands to 
interact with receptors on cells 
Immunoliposomes 
Grafted with monoclonal antibodies for 
targeted drug delivery 
 Transferosomes 
With high elasticity to improve skin 
permeation following topical delivery 
 Ethosomes 
Utilize ethanol’s penetration properties 
to improve skin penetration 
 Pharmacosomes 
Contain drugs that bind to 
phospholipids to improve their 
bioavailability 
 Emulsomes 
Contain a solid fat core to improve 
stability and entrapment efficiency 
 Niosomes 
Contain nonionic surfactants to improve 
oral bioavailability of drugs 
 Vesosomes 
Contain multiple compartments with an 
external bilayer to protect drugs from 










Figure 1.6.  Schematic of liposome surface modification strategies. (A) Conventional liposomes. 
(B) Stealth liposomes (PEGylated liposomes). (C) Multifunctional liposomes. (D) Ligand targeted 
liposomes. [99] 
 
1.3.5.1 Conventional liposomes.  Conventional liposomes, also referred as the ‘first 
generation liposomes”, are usually composed of neutral or anionic phospholipids and cholesterol 
[83, 100].  Although their lipid bilayers are similar as biological membranes, they are detected by 
the immune system as foreign objects.  After administrated through IV injection, conventional 
liposomes are recognized and rapidly captured by the reticuloendothelial system (RES), leading 
to their quick clearance and short half-life [46].  Conventional liposomes have been utilized for 
antiparasitic and antimicrobial drug delivery [101].  Nevertheless, RES becomes the major site of 
conventional liposome accumulation, resulting in their minimal effect on cells beyond RES.  
Conventional liposomes with larger size showed enhanced RES uptake, especially in the liver, 
which elevated the hepatic clearance [102].  Furthermore, conventional liposomes, especially 
those without cholesterol, displayed poor stability and poor extravasation after injection, due to 
their physical interaction with lipoproteins other serum proteins [83, 103].  
a. Conventional Liposome b. Stealth Liposome 





1.3.5.2 Stealth liposomes.  In order to overcome the aforementioned drawback of 
conventional liposomes, the surface of liposomes was modified to prolong their circulation in 
blood.  The extended circulation time can be achieved by coating the liposomes with inert, 
hydrophilic polymers, such as polyethylene glycol (PEG), which provides a protective shell to 
hinder adsorption of serum proteins and elimination by RES.  Owing to the PEG coating, the 
liposomes are less “visible” to RES, thus earning them the distinction as stealth liposomes [80] 
[83].  The hydrophilic PEG is also known to bind with water molecules via hydrogen bonding, 
which results in a hydration film that surrounds the liposome to mitigate its interaction with RES 
[51].  Moreover, the long chains of PEG surrounding a liposome provide a strong repulsion to 
the bilayer of other liposomes and thus prevent liposome aggregation, leading to improvement of 
liposome stability [104].  These multiple mechanisms of the PEGylated liposomes help them stay 
in the blood circulation for a longer period of time.  Stealth liposomes have demonstrated dose-
independent and non-saturable kinetics, as well as improved bioavailability [105].   
PEG can be introduced onto liposome surface in multiple ways, including a) physical 
adsorption onto liposomes, b) covalent binding to liposomes, and c) addition of PEGylated lipids 
in the bilayer composition during liposome preparation.  Stealth liposomes can be prepared using 
various lengths of PEG chains, which can substantially influence the liposome properties.  
Generally, the higher molecular weight of PEG leads to longer circulation time, except that liver 
clearance is found to be increased when the average molecular weight of PEG goes over 50000 
Da [106].  PEG molecules ranging 2000 – 5000 Da have been extensively utilized in the 
preparation of stealth liposomes [107].  Besides PEG length, the performance of stealth 
liposomes in vivo is also influenced by other physicochemical properties, such as their size.  It 





property is significantly compromised [108].  Stealth liposomes with diameter of 100-150 nm 
were found to display notably reduced interaction with opsonins and other proteins in plasma 
[79, 109, 110].   
Stealth liposomes are important in cancer treatment because their properties support 
passive targeting of their payload drugs.  By minimizing the interaction of with RES, the stealth 
liposomes are targeted to tumor tissues more than RES.  With PEG functionalization, the half-life 
of liposomes in blood circulation was extended from a few minutes to several hours [79].  The 
EPR effect is principally correlated to circulating time, and thus can be enhanced in stealth 
liposomes thanks to the sufficient time for such liposomes to circulate and to accumulate in 
tumor tissues.  The preferential accumulation of stealth liposomes in tumor tissues leads to 
highly concentrated payload drugs at the target site and hence improvement in therapeutic 
efficacy over conventional liposomes.   
Despite the prolonged circulation time and improved passive targeting of stealth 
liposomes, the steric hindrance of PEG chains decreases the interaction of liposomes with tumor 
cells [111], which in turn decreases intracellular uptake of the liposomal drug.  To overcome this 
challenge, active targeting strategies, either ligand-receptor binding or locally activated drug 
delivery, has been applied along with the passive targeting to improve the drug delivery.  The 
ligand-receptor mediated active targeting can be introduced by modifying the surface of stealth 
liposomes with targeting ligands.  With the targeting ligands attached, the stealth liposomes 
would have significantly more interaction with tumor cells that overexpress the corresponding 
receptor [85].  Moreover, because the stealth liposomes can lodge in the interstitial spaces 
between the tumor cells, some elaborate targeting ligands were utilized to deliver the liposomes 





molecules that can trigger the liposomes in response to specific local stimuli. Stimulus-triggered 
release is the most common mechanism of action by stimulus-sensitive systems.   
It must be noted that long circulation time is not always desirable for liposomes because 
it may also cause additional toxicity other than that of the cytotoxic payload [98].  For example, 
Doxil®, the approved stealth liposomal DOX, has much longer half-life (2-3 days) than free 
DOX (0.2 hour).  The prolonged circulation time and passive targeting makes Doxil a suitable 
medicine for skin treatment of localized cancers such as Kaposi’s sarcoma [83].  However, 
despite its significantly lower cardiotoxicity, myelosuppression and nausea than free DOX, Doxil 
has other significant side effects, such as Palmar-plantar erythrodysesthesia (PPE) and mucositis 
[81], which are largely attributed to its reduced clearance and tendency to accumulate at the skin 
[112].  In contrast, Myocet™, the approved conventional liposomal DOX with a much shorter 
half-life (2-3 hours) is not associated with PPE and has remarkably reduced incidence of 
mucositis [113]. Still, Myocet has sufficient circulation time to allow effective passive targeting 
to tumor sites, as demonstrated in studies on its use against metastatic breast cancer [80].  Stealth 
liposome-based and conventional liposome-based delivery systems are both under heavy 
development and have both yielded approved nanomedicines.  These two types of liposomes are 
used to treat different diseases due to their different features so neither one would be able to 
substitute the other.   
1.3.5.3 Stimulus-sensitive liposomes.  Triggered release is a strategy to enhance the 
payload drug exposure to target cells and hence to improve the therapeutic outcome of liposomal 
formulations [114].  To achieve triggered release, liposomes are functionalized with specific 
molecules, thus become sensitive to target-specific stimuli and can release the cargo agents upon 





The internal stimuli are endogenous signals that are specifically presented at or near the 
diseased sites, including pH, redox potentials, temperature, and enzymes.  The pH gradients in 
tumor interstitium and endosomes have been widely utilized to trigger extracellular and 
intracellular release of payload agents from pH-sensitive liposomes [23, 114]. Liposomes can 
also be triggered in tumor tissues by their lower redox potential due to their hypoxia condition 
[60].  Thermo-liposomes can elevate their drug release when stimulated by higher temperature in 
inflammatory tissues [115] or by hyperthermia treatment of tumors [116].  In endosomes, 
hyaluronidase, the enzyme that degrades hyaluronic acid (HA), can trigger endosomal escape of 
HA-coated liposomes [94].   
The external stimuli include ultrasounds, light, magnetic field and electric field. Such 
stimuli are applied for spatiotemporal control.  It was found alternating magnetic field (AMF) 
can trigger the self-heating of liposome-encapsulated iron oxide nanoparticles to permeate the 
liposome membrane and hence to enhance the content release [117].  Ultrasound was found to 
expand gas pockets and thus was used to  permeate the membrane of liposomes that co-
encapsulate drugs  and gas bubbles [118].  
1.3.5.4 pH-sensitive liposomes.  pH-sensitive liposomes have been developed to respond 
to the change of pH in specific biological microenvironments.  pH gradients in the body have 
been investigated as an internal stimulus for drug delivery systems.  The gastrointestinal (GI) 
track has a broad range of pH, from 1-3 in stomach, to 6 in duodenum, and to 7-8 in jejunum and 
ileum [119].  The tumor tissues have lower pHe than normal tissues (pH 7.4), ranging from 5.8 to 
7.6 and averaging around 7.0 [14].  The highly hypoxic core in tumors generally displays pHe 
6.1-6.4 [15].  pH decrease is also found during endosome maturation: from 7.4 to 6.5 in early 







Figure 1.7.  Schematic of two levels of pH-triggered responses of liposomes. (a) pH-triggered drug 
release in tumor interstisium [121]. 1) Liposomes are not able to extravasate to healthy tissues. 2) 
Liposomes extravasate to tumor tissues through the more porous tumor blood vessels. 3) 
Liposomes are retained in the tumor microenvironment. 4) Triggered release in response to acidic 
pH in tumor interstitium. (b) pH-triggered endosomal escape in cytoplasm [122]. 1) Direct fusion 
pathway of liposomes. 2) Endocytosis pathway of liposomes. 3) Maturation process of endosomes. 
4) pH-Triggered endosomal/lysosomal escape.  
 
Mechanistically, pH-sensitive liposomes undergo rapid destabilization in acidic 
environments to exert their biological activities [114].  The methods of inducing pH-sensitivity 
include incorporation of pH-sensitive lipids (such as DOPE or synthetic novel lipids) in the 
liposome membrane, conjugation with pH-sensitive molecules such as polymers and peptides, 
and encapsulation of pH-sensitive substances such as nanoparticles and peptides [23].  The pH-
triggered actions of liposomes include content release, interactions with cells (such as binding, 
membrane fusion, and endocytosis), and endosomal escape.  For some examples, pH-induced 
conformational flip of cyclohexane ring was utilized to produce a novel pH-sensitive lipid, which 
can permeate liposome membranes when exposed to the acidic microenvironment in tumor 
interstitium, thereby enhancing the release of the cargo drugs [123]; pH-sensitive alkylated N-







































onto liposome surface as a polymer coating [124]; magnesium phosphate nanoparticles that were 
co-encapsulated in liposomes were found to dissolve at lowered pH in endosomes to increase the 
osmotic pressure, which in turn help the cargo agents to escape the endosome [93].  
1.3.6 Imidazole-based convertible liposomes (ICL).  Although the PEG coating of 
liposomes helps to overcome the short circulation time and RES clearance to enhance tumor 
accumulation, the steric hindrance of the PEG coating also reduces the liposome’s interaction 
with the cancer cells [125].  An ideal liposomal formulation is expected to carry not only high 
stability and sufficient accumulation in tumor tissues, but also good interaction with cancer cells 
to improve their penetration into solid tumors and their cargo’s intracellular uptake.  If a 
liposome carries the PEG coating in blood circulation and yet removes the coating upon 
exposure to cancer cells, then it can first accumulate at tumor sites and then interaction with 
cancer cells.  Specific stimuli from tumor sites, such as acidic pH, can trigger this conversion.   
Previously, various PEG-shedding strategies were reported [126].  pH-sensitive linkers that can 
be hydrolyzed at acidic pH were used to detach the PEG molecules from liposome surface.  
However, such hydrolysable liposomes showed either poor stability at physiological pH 7.4 or 
insufficient pH-sensitivity at the mildly acidic pH 6.0 in tumor interstitium.  Recently, our group 
developed a novel pH-sensitive liposome, whose grafted PEG chains are clustered rather than 
shed at acidic pH, is expected to be stable at physiological pH 7.4 but also activated to improve 







Figure 1.8.  Schematic of two strategies to reduce the steric hindrance of PEG coating of stealth 
liposomes at acidic pH: PEG shedding (right upper) and PEG clustering (right lower).  
 
Instead of using hydrolysable linkers to shed the PEG coating at acidic pH, this novel 
liposome contains 25 mol% of a synthetic lipid with an imidazole headgroup and two C16 
hydrocarbon chains, which can protonate to display positive charges in response to acidic pH 
(Figure 1.9).  This novel liposome also consists of DPPE-PEG (5 mol %), which is a PEGylated 
C16 phospholipid with a negative charge on the Phosphatidylethanolamine (PE) headgroups.  
The liposome also consists of a neutrally charged C18 phospholipid DSPC (70 mol %) (Figure 
1.9).  Due to electrostatic attraction between the headgroups and Vander Waals forces between 
the lipid tails of the same length [127], the positively charged imidazole-based lipids (C16) can 
cluster with the negatively charged DPPE-PEG (C16) (Figure 1.8) to expose part of the liposome 
surface free of PEG coating to interact with cancer cells.  Moreover, the protonated imidazole-
based liposomes display excess positive charges to interact more with cell membranes, which are 
negatively charged [128] (Figure 1.10).  Such novel liposomes would show the stealth properties 
at physiological pH 7.4 but converts into cationic liposomes at acidic pH in tumor interstitium.  
Such liposomes are named imidazole-based convertible liposomes (ICL) [129].  
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Figure 1.9. Chemical structures of lipids that constitute ICL: (1,2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000 (DPPE-PEG) (C16, negatively 
charged), the imidazole based lipids DHI/DHMI/DHDMI (C16, positively charged at acidic pH), 
and 1,2-distearoyl-snglycero-3-phosphocholine (DSPC) (C18, neutral).  At acidic pH, the 




Figure 1.10.  Schematic of ICL turning from stealth liposomes into cationic liposomes. ICL 
contains negatively charged DPPE-PEG (shown by ‘P’), imidazole lipids (shown by ‘N’), and 
neutral DSPC.  In blood circulation (at pH 7.4), the ICL are coated with a PEG shell to prolong 
their circulation time (left).  When the ICL are delivered into tumor tissue (at pH 6.0-7.0), the  
R1 = H, R2 = H          DHI 
R1 = H, R2 = CH3       DHMI 
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(Figure 1.10 Continued) 
imidazole lipids are protonated (shown by ‘N+’) and therefore cluster with DPPE-PEG to expose 
a domain with excess positive charges and without the PEG shell.  Such cationic liposomes would 
have greater interaction with cancer cells.  
 
1.4 3D Multicellular Spheroids (MCS) 
1.4.1 2D and 3D cell culture systems.  Traditionally, the in vitro processes which are 
used to assess the activity of anticancer drug are two-dimensional (2D) monolayer cancer cells. 
Besides cancer research, 2D cell culture systems have also been broadly applied in other fields of 
biological and medical sciences, such as basic cellular research, stem cell research and 
regenerative medicine.  2D cell culture systems have many advantages, including high efficiency, 
low cost and convenient operation.  However, the 2D monolayers cell culture cannot adequately 
simulate many features of solid tumors, such as cell-cell interactions, tissue hypoxia and ECM 
[130, 131].  It has been found the 2D cell culture systems are not always predictive of the clinical 
performance of new drug candidates. Poor correlation is also noted between the outcomes from 
2D monolayer cell models in vitro and on those from animal models in vivo.  Because 2D 
monolayer cells lack the solid structures or the complex dynamics of material transport in real 
tumors, they are also substantially different in many other functions such as proliferation and 
responses to external stimuli [132].   
However, in vitro cell culture models are still widely used because of their low cost and 
high efficiency, especially in high throughput screenings (HTS) [133].  Three-dimensional (3D) 
cell cultures allow the cells can grow and interact with their surroundings in all three dimensions, 
similar to how they would in vivo [134].  3D culture systems are usually conduced in small 
capsules or bioreactors where the growing cells would form spheroids or 3D cell colonies.  3D 





models for drug discovery owing to their huge translational potentials [135, 136].  The 
establishment of 3D cell culture models is focused on the physiologically relevant multicellular 
structures and the ECM, which is more relevant than 2D cell culture systems for validating cell 
responses to therapeutics.  3D cell culture models are able to resemble not only the 3D 
morphology of solid tissues but also the complex tissue properties including cell connectivity, 
tissue architecture, and even gene expression, all serving to better bridge between in vitro and in 
vivo models.   
Among the 3D models, multicellular spheroids (MCS) are the most accessible, 
economical and versatile due to their diverse and relatively simple preparation methods [136].  
3D MCS, also known as spheroids, are spherical constructs composed of self-assembled cells.  
Many 2D monolayer cell cultures have been adapted to construct spheroids systems,  including 
multicellular tumor spheroids (MCTS), neurospheres, mammospheres, hepatospheres and 
embryoid bodies [133, 137].  Besides cancer research, 3D cell culture techniques have also been 
commonly applied to stem cell research and tissue engineering.  
1.4.2 Similarity between MCTS and solid tumors.  The best-characterized 3D cell 
culture technique in anticancer research is MCTS, which is derived from cancer cell lines 
commonly used in 2D culture [138].  MCTS are more representative in vitro models of solid 
tumors than 2D monolayer cells, due to their solid morphology, gradients of oxygen, nutrients 
and pH, heterogeneous cell viability, cell-cell interaction, and complex ECM [138, 139].  Owing 
to the above biological features, MCTS have been utilized to study solid tumor biology and to 
establish platforms to screen for anticancer drugs.  
1.4.2.1 Three gradients and three layers of cell organization.  Similar with in vivo solid 





organization – proliferating, quiescent, and necrotic cell layers. Owing to the dense solid 
constructs of aggregated cells, penetration of oxygen and nutrients are limited in MCTS.  The 
hypoxic characteristic of MCTS has been well adapted to assess oxygen-dependent therapeutics.  
For example, many studies explored the sensitivity of MCTS to radiation in order to effectively 
predict the clinical responsiveness of solid tumors to radiotherapy, because hypoxia was found to 
be a major contributor to the radio-resistance of tumor cells [140, 141].  
The pH gradients in MCTS are attributed to insufficient penetration of oxygen and 
nutrients. Without adequate oxygen and nutrients, metabolic pathways in MCTS to favor 
anaerobic metabolism while the removal of metabolic waste is  enfeebled, jointly leading to an 
accumulation of metabolic by-products of hypoxia, mostly lactate [142].  Thus, similar with solid 
tumors, MCTS carry acidic interstitial pH, especially in the core.  Such lowered pH of MCTS 
allows better understanding of tumor biology and better evaluation of anticancer therapeutics.  
The vasculature-free “microtumors” mimicked by MCTS are composed of three layers of cells - 
proliferating cells at the periphery, quiescent cells right below the proliferating cells, and necrotic 
cells in the MCTS core.  Such a three-layer cellular structure of MCTS is similar to the avascular 
regions in solid tumors (Figure 1.11) [22].  The three-layer cell organization of MCTS is closely 
correlated to the gradients of oxygen, nutrients and pH, and primarily relies on the volume and 
growth rate of spheroids.  MCTS larger than 500 µm were found to assume this three-layer cell 
organization [143, 144].  MCTS with diameter below 120 µm were found well oxygenated, but 
as they grow larger, the concentrations of oxygen and nutrients in the inner core decrease rapidly.  
Subsequently, the MCTS interstitial pH also decreases, followed by the decrease of cell viability 
[145].  Both the hypoxia and the necrosis characteristics of MCTS closely mimic their 






Figure 1.11.  Schematic representation of bio-similarity between MCTS (left) and solid tumor 
(right). [22] 
 
1.4.2.2 ECM, cell-cell and cell-ECM interactions.  The extracellular matrix (ECM) is a 
major structural component in tumor microenvironment.  ECM contains proteins and 
polysaccharides to provide cells with essential physical and biochemical support.  The traditional 
2D monolayer cell cultures cannot mimic the microenvironment in solid tumors because of their 
much weaker cell-cell and cell-ECM interactions, which often  makes them unreliable models to 
evaluate drug efficacy and toxicity [147].  The in vivo-like MCTS models would overcome some 
of these limitations.  Various types of ECM components, including structural (collagen and 
elastin) and adhesive (fibronectin and laminin) proteins, are found in MCTS in similar 
proportions as those in solid tumors.  Such components have been found as critical factors to 
define the interaction between MCTS and drugs [148, 149].  Because of the importance of ECM 
to cell survival, proliferation, and migration, MCTS have been utilized to investigate not only the 
mechanisms of cell migration and invasiveness in tumors but also the therapeutics applied to 












MCTS construction.  Some cancer cells can produce adequate ECM substrates for self-
assembling while some cancer cells cannot [151].  Cancer cells that do not produce sufficient 
ECM substrates can be assisted by scaffold materials to establish their MCTS.  Biocompatible, 
natural polymers such as collagen, fibrin and Matrigel are utilized as scaffolds to construct ECM-
embedded MCS models because those polymers intrinsically contain ECM components, 
including growth factors (GFs) and laminin [136].  Despite the advantages of 3D MCTS over 2D 
cell culture from their ECM, it should be noted that the ECM substrates in MCTS originate 
differently compared to those in solid tumors in that the former are generated by cancers cells or 
added extrinsically, while the latter are secreted by fibroblasts [152].  To better study the cell-
ECM interactions in tumors as well as their impact on anticancer treatments, MCTS co-cultured 
with stromal components (e.g. fibroblast, macrophages and endothelial cells) have been 
developed as the more in vivo-like models that mimic the heterogeneity of tumor tissues [153].   
1.4.2.3 Drug penetration and drug resistance.  3D MCTS models have become more 
predictive tools for drug screening because they can mimic the restricted intratumoral drug 
penetration, which is a large contributor for drug resistance in vivo [137].  The microenvironment 
forcell-cell and cell-ECM interactions in MCTS closely mimics the permeability barriers in solid 
tumors [149].  Moreover, the hypoxic regions seen in both solid tumors and MCTS was found to 
limit the penetration of anticancer drugs by boosting their local degradation/metabolism [154, 
155].  Drug penetration into MCTS was studied under tunable hypoxic conditions that were 
controlled by extrinsic hypoxia-reoxygenation cycling, which showed poor drug penetration into 
hypoxic spheroids and increased penetration and cellular uptake of drugs in reoxygenated 
spheroids [156].  Together, hypoxia, necrosis and acidic pH all contribute to drug resistance in 





3D MCTS should greatly benefit the development and clinical translation of anticancer 
nanomedicines due to their unique physicochemical properties.  MCTS provide a solid construct, 
which can provide the in vivo-like interaction with nano drug carriers.  Because the 
physicochemical properties (size, shape, surface, etc) of nano drug carriers greatly affect their 
interaction with tumor cells, such properties can be optimized according to their effects in MCTS 
models [157, 158].  MCTS also contains ECM which provides highly in vivo-like physical and 
biochemical barriers for nanomedicines.  Nanomedicines can be designed and developed to 
overcome such impediment from ECM based on the in vitro data from the ECM of MCTS.  
Lastly, MCTS containing ECM stromal cells are considered even more clinically relevant.  For 
example, Doxil® was reported to have reduced penetration into MCTS of breast cancer cells 
when the MCTS also contains fibroblasts [159].   
1.4.3 3D cell culture techniques.  3D cell culture can be constructed by many 
techniques, which can be grouped into scaffold-based techniques and scaffold-free techniques.   
1.4.3.1 Scaffold-based techniques.  Scaffold-based techniques are also known as matrix-
based techniques, which refer to the utilization of solid scaffolds, hydrogels and other materials 
to provide the structural support.  For example, hydrogels, which provide high moisture retention 
and interconnected pores, allows adequate gas exchange and nutrient supply in a way similar to 
natural ECM structures in tissues [160].  Agarose gel was used to generate a 3D model to 
understand the bone ossification process and potential of human CD34+ stem cells.  Scaffolds 
can also play as vehicles to control the delivery of drugs, proteins and DNA [151, 161].   
Scaffold-based 3D cell culture still faces several challenges, including poor initial cell 
density in the constructed tissues, and improper usage of scaffold materials [162].  Some 





scaffolds may also induce biodegradation, which is triggered by inflammatory responses of the 
cultured cells.  Scaffolds with too small pores would limit transport of oxygen, nutrients, and 
waste, resulting in poor cell survival and proliferation.  The surface properties of scaffold 
materials would also affect cell adhesion, proliferation, aggregation, and functions [163].  Taken 
together, significant factors to consider when choosing scaffold materials include their cell 
interaction, porous size, and surface properties.  Matrix materials such as Matrigel and HA are 
considered as ideal scaffolds for 3D cell culture, which are biocompatible and can provide 
growth factors and signal factors to promote cell proliferation [137, 164].  
Scaffold-based techniques have been extensively applied in tissue regeneration and cell 
transplantation.  They have limited capability to construct 3D MCS, due to the inhomogeneous 
distribution of cells seeded in the porous scaffold and the lower initial seeding density compared 
with scaffold-free techniques [165].  However, the scaffold-free methods with the addition of 
scaffold/matrix materials, such as collagen and Matrigel, have been extensively applied to 
construct MCS tumor models using cancer cells that produce limited ECM substrates [136, 166].   
1.4.3.2 Scaffold-free techniques.  Scaffold-free techniques are methods to construct 3D 
culture models without dependence on scaffold materials.  This strategy relies on the inherent 
ability of the culturing apparatus to assemble cells into larger structures [165].  Available 
scaffold-free methods (Figure 1.2) include hanging-drop, forced-floating (low adhesion surface), 
agitation-based bioreactors (spinning flask and rotating culture), force-driven approaches 
(magnet, electric and acoustic), cell sheets and bioprinting [137, 164].   
Scaffold-free techniques have been developing faster than scaffold-based techniques due 
to a number of advantages[167].  With external rigid support, scaffold-free techniques can 





construct 3D models by scaffold-free methods because the initial cell seeding density is much 
higher than scaffold-based methods.  Consequently, cell proliferation and migration are not 
crucial factors for the 3D MCS construction.  Compared with time-consuming scaffold-based 
methods, which use scaffold materials that may be biodegradable, scaffold-free methods are 
considered as faster, safer, and more reliable techniques [168].   
Furthermore, scaffold-free methods have been used to construct not only 3D MCS of one 
type of cells but also those of multiple types of co-cultured cells in order to simulate the 
complexity of tissue and organ architecture [167].  Some 3D co-culture spheroids are composed 
of both cancer cells and other cells known to be involved in tumor progression, such as 
fibroblasts, macrophages, monocytes, endothelia and immune cells. Such co-culture MCTS can 




Figure 1.12.  Common methods to construct 3D MCS.  (a) Low adhesion plates.  (b) Hanging-
drop.  (c) Spinning flask.  (d) Rotating culture.  [164] 
 
1.5 Hypothesis and Specific Aims.  
Based on the foregoing, the hypothesis of this thesis is that compared with conventional 













based lipids can express better anticancer activity in vitro.  To test this hypothesis, this project 
has the following specific aims:  
1. To prepare, optimize and characterize the imidazole-based convertible liposomes (ICL).  
2. To test the pH-sensitivity of ICL.  
3. To study the morphology of ICL using transmission electron microscopy (TEM) 












CHAPTER 2:  PREPARATION AND PHYSICOCHEMICAL CHARACTERIZATION OF 
IMIDAZOLE-BASED CONVERTIBLE LIPOSOMES 
 
2.1 Introduction 
Liposomal formulations have been reported to carry considerable advantages, including 
high loading capacity of drugs, capability to carry either hydrophilic or lipophilic payload drugs, 
relatively long half lives in blood circulation, and targeting to tumors [171].  The stealth liposomes, 
which contain PEGylated lipids to form a surface coating of the PEG polymers, can achieve longer 
half-life in blood circulation than conventional liposomes by sterically hindering their recognition 
by reticuloendothelial system (RES) [172].  The increased half-life allows the stealth liposomes to 
accumulate more in the perivascular environment in solid tumors, a phenomenon known as the 
enhanced permeation and retention (EPR) effect.  However, the steric hindrance of the PEGylated 
stealth liposomes also decreases their interaction with cancer cells [125].  To increase the liposome-
cancer cell interaction and thus to improve the intracellular delivery of the payload drug, three 
imidazole-based ether lipids were developed in our group to be protonated at the acidic 
microenvironment of the tumor interstitium.  At acidic pH, the PEGylated stealth liposomes 
containing the imidazole-based lipids would convert to cationic liposomes, thus given the name 
imidazole-based convertible liposomes (ICL).  The cationic liposomes thus formed at acidic pH in 
the tumor microenvironment would then better interact with the negatively charged cell membrane 
[40].   
The studies reported in this chapter aim to develop more robust methods to prepare DOX-
loaded ICL for anticancer drug delivery.  Various PEGylated liposomes containing imidazole-
based ether lipids were constructed to investigate the effect of multiple factors on the 





2.1.1 Design of the imidazole-based ether lipids.  The imidazole headgroup has been 
chosen to conjugate with the two C16 hydrocarbon chains due to its unique properties.  The N3 of 
the imidazole moiety is basic (estimated pKa 5.5-6.8) and thus would protonate at mildly acidic 
pH.  The protonation of imidazole would then provide positive charges to the lipid molecules, 
which would then interact with the negatively charged PEGylated lipid molecules.  The imidazole 
lipids and the PEG-lipid conjugate (DPPE-PEG) all carry C16 hydrocarbon chains to further 
enhance their Van Der Waals interactions. 
 
 
Figure 2.1.  Structures of the imidazole-based ether lipids.  
 
2.1.2 The composition of ICL.  The imidazole-based convertible liposomes (ICL) 
contain DSPC (C18), imidazole-based lipids (C16) and DPPE-PEG (2000) (C16).  In our studies 
that investigated the influence by cholesterol, 25% cholesterol were added in place of the same 
mole percentage of DSPC.  ICL were studied in comparison with a non-sensitive liposomes 
(NSL), which contains no imidazole-based lipids. The lipid composition of ICL and NSL without 










Lipid composition of ICL and NSL formulations without and with cholesterol 
 Mol % 
Formulations DHI DHMI DHDMI DSPC DPPE-PEG Chol 
I 25 - - 70 5 - 
II - 25  70 5 - 
III - - 25 70 5 - 
IV - - - 95 5 - 
V 25 - - 45 5 25 
VI - 25 - 45 5 25 
VII - - 25 45 5 25 
VIII - - - 70 5 25 
 
2.1.3 The phase transition temperature of ICL.  The phase behavior of lipid bilayers 
has been widely acknowledged as property about the mobility of individual lipid molecules in 
response to temperature [173].  Generally, a lipid bilayer can exist in either gel phase or fluid 
phase at a certain temperature.  The gel phase is commonly known as lipid bilayers composed of 
lipids in solid state.  The fluid phase, also known as the liquid crystal phase, is known as lipid 
bilayers composed of lipids in liquid state.  Same as in gel phase, the lipid molecules in fluid 
phase bilayers are constrained to the lateral plane of membranes.  However, the lipid molecules 
in the fluid phase, but not those in the gel phase, have free lateral diffusion within their 
monolayer.  The temperature at which a specific lipid transits from the ordered gel phase to the 
disordered fluid phase is defined as its phase transition temperature (Tm) [174].  The Tm value of 
a lipid was found to be a function of the length of its acyl chains and its saturation [175].  Table 
2.2 shows that phospholipids with longer acyl chains and less unsaturated bones bonds would 





Table 2.2. Hydrocarbon length, unsaturated and Tm of lipids with PC and PE headgroups [176] 
Lipids Length of Acyl Chains Unsaturated Bones Tm (˚C) 
DLPC 12 0 -2 
DMPC 14 0 24 
DPPC 16 0 41 
DSPC 18 0 55 
DOPC 18 1 -17 
DLPE 12 0 29 
DMPE 14 0 50 
DPPE 16 0 63 
DSPE 18 0 74 
DOPE 18 1 -16 
 
According to Table 2.2, the Tm of DSPC and DPPE are 55˚C and 63˚C, respectively.  The 
Tm of a liposomal bilayer is determined by the Tm of the component lipids [177].  Concisely, Tm 
of a bilayer system was defined as the temperature at which half of the substance is in its fluid 
state, while the other half is in its gel state [177].  The shift of Tm of a lipid bilayer after 
incorporation of PEGylated lipids can be attributed to the mismatch of acyl chain length and the 
negative effect of PEG [178].  For PEGylated lipids containing shorter polymers (up to 3000), 
their acyl chains determine their effect on the Tm, while for PEGylated lipids containing longer 
polymers (> 3000), their PEG chains determine their effect on the Tm.  Accordingly, the Tm of 
DPPE-PEG (2000) should be close to the Tm of DPPE (63˚C).  The Tm of imidazole-based lipids 
(C16) is estimated to be lower than that of DSPC (55˚C), due to their shorter acyl chains.  Based 
on the foregoing, we estimated that the Tm of our ICL liposomal bilayer would be around 63˚C.  
Therefore, the temperature during the ICL preparation was set at 70˚C to ensure that the bilayer 





2.2 Materials and Methods 
2.2.1 Materials.  1,2-Di-O-hexadecyl-rac-glycerol (DHG), 2- Mercaptoimidazole, 4-
Methyl-1H-imidazole-2-thiol and 4,5-Dimethyl-1H-imidazole-2-thiol were purchased from 
Santa Cruz Biotechnology (Dallas, TX, US). pToluenesulfonyl chloride, dichloromethane 
(anhydrous), pyridine (anhydrous), DMF (anhydrous) and 2-[4-(2-hydroxyethyl)piperazin-1-yl]-
ethanesulfonic acid (HEPES) were purchased from Fisher Scientific (Hampton, NH, US).  
Triethylamine (TEA) and Silica Gel 60 (230-450 mesh) were purchased from Alfa Aesar 
(Haverhill, MA, US).  The lipids 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-
dipalmitoyl-snglycero-3-phosphoethanolamine-N-[azido(polyethylene glycol)-2000 (DPPE-PEG 
(2000)), and 1,2 dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) were purchased from Avanti 
Polar Lipids, Inc. (Alabaster, AL, USA).  Cholesterol, Dowex® 50WX-4 (50-100 mesh), and 
Sephadex G-25 were purchased from Sigma-Aldrich (St. Louis, MO, USA).  Doxorubicin 
Hydrochloride was purchased from Biotang (Waltham, MA, USA).  All other organic solvent 
and chemicals were purchased from Sigma Aldrich, Fisher Scientific or VWR. 
2.2.2 Synthesis of imidazole-based ether lipids.  
2.2.2.1 Synthesis of 1,2-Di-O-hexadecyl-rac-glyceryl tosylate (DHG Tosylate).  1,2-Di-
O-hexadecyl-rac-glycerol (DHG) (2.30 g, 4.25 mmol, 1 equiv) was dissolved in 20 mL 
anhydrous dichloromethane, coupled with pyridine (18.6 mL, 225 mmol, 50 equiv).  p-
Toluenesulfonyl chloride (1.90 g, 9.97 mmol, 2 equiv) was dissolved in small amount of dry 
dichloromethane and transferred to the above solution.  The apparatus and solid reagents were 
dried under high vacuo at room temperature for over 4 hours the dry solvents and solutions were 
transferred by Hamilton syringe or double-pointed needles under argon.  The reaction mixture 





silica gel TLC (Fisher Scientific, Hampton, NH, US) using dichloromethane as the mobile phase. 
The reaction mixture was then mixed well with 10 ml anhydrous dichloromethane and washed 
with saturated sodium carbonate solution for 3 times.  The organic phase was separated from the 
aqueous phase and was then dried with magnesium sulfate.  The dried solution of the reaction 
mixture was filtered and then evaporated into dryness under vacuum.  The resultant residue was 
then seperated by silica gel chromatography with dichloromethane as the mobile phase to yield 
2.53 g DHG-tosylate solid. (Yield 86%).  
2.2.2.2 Synthesis of sn-2-((2,3-bis(hexadecyloxy)propyl)thio)-1H-imidazole 
(DHI), sn-2-((2,3-bis(hexadecyloxy)propyl)thio)-5-methyl-1Himidazole (DHMI) and sn-2-
((2,3-bis(hexadecyloxy)propyl)thio)-4,5-methyl-1Himidazole (DHDMI).  In order to achieve the 
anhydrous conditions for the reactions, the glass apparatus and reagents were pre-dried in high 
vacuum for over 4 hours, and transfers of liquid were handled by air-tight Hamilton syringe and 
double-pointed needles under argon.  2- Mercaptoimidazole (0.91 g, 9.06 mmol, 5 equiv.), 4-
Methyl-1H-imidazole-2-thiol (1.03 g, 9.03 mmol, 5 equiv.), or 4,5-Dimethyl-1H-imidazole-2-
thiol (1.15 g, 9.03 mmol, 5 equiv.) was dissolved in 8-9 mL N,N-Dimethylformamide (DMF).  
DHG-tosylate (1.265 g, 1.82 mmol, 1 equiv) was dissolved in 7-8 ml of dry dichloromethane and 
transferred into the above-mentioned solution, followed by addition of Triethylamine (TEA) 
(1.27 mL, 9.08 mmol, 5 equiv.).  The reaction mixture was stirred under argon at 55˚C for 48 
hours.  The reaction was monitored by TLC (silica gel plate) and UV with 5/95 (v/v) 
methanol/dichloromethane or ethyl 3/7 (v/v) acetate/hexane as the mobile phase.  The solvent 
was evaporated under vacuum and the resultant residue was dissolved in dichloromethane.  The 
solution was washed with saturated sodium bicarbonate solution for 3 times, dried with sodium 





then separated by silica gel chromatography with 1-5% (v/v) methanol/dichloromethane as the 




Figure 2.2.  Synthesis of imidazole-based lipids DHI, DHMI and DHDMI.  
 
2.2.3 Preparation of ICL formulations. 
2.2.3.1 Preparation of liposomes.  Generally, the liposomes were prepared using film 
hydration, freeze-anneal-thawing and extrusion methods.  A dichloromethane solution of 
imidazole-based ether lipids and a chloroform solution of other lipids were mixed in a recovery 
flask.  The organic solvents were evaporated under reduced pressure to form a lipidic film on a 
Buchi rotavapor at 70˚C.  The lipidic film was further dried in vacuum for over 4 hours at room 
temperature to remove the residual solvent completely.  The lipidic film was then hydrated with 
isotonic HEPES buffer (pH 7.4, 5 mM HEPES, 140 mM NaCl) by intermittent agitation in a 
70˚C water bath to obtain a liposomes suspension containing 20 mM total lipids.  The flask was 
filled with argon and sealed with parafilm.  The Liposome suspension was freeze-anneal-thawed 
by rapidly freezing in liquid nitrogen, emerging in ice-water mixture for 2 min and incubating in 
DHI            R1 = H, R2 = H 
DHMI        R1 = H, R2 = CH3 





70˚C water bath for 4 min.  The freeze-anneal-thawing was repeated for 11 times.  The liposome 
suspension was sequentially extruded 21 times each though 400 nm, 200 nm and 100 nm 
polycarbonate membranes (Nucleopore Corp., Pleasanton, CA, US) using a hand-held Mini-
extruder (Avanti Polar Lipids Inc., Alabaster, AL, US) at 70° C to reduce and homogenize the 
sizes of liposomes.  The resultant liposome suspensions were stored at 4˚C in glass vials filled 
with argon and sealed with parafilm until further studies.  
2.2.3.2 DOX loading into liposomes by manganese sulfate gradient.  The 
transmembrane manganese sulfate gradient was used to load DOX into liposomes.  The lipidic 
film in 2.2.3.1 was hydrated with HEPES buffer (pH 7.4, 30 mM HEPES) containing 300 mM 
manganese sulfate by intermittent agitation in a 70˚C water bath to obtain a liposomes 
suspension containing 20 mM total lipids.  The freeze-anneal-thawing and extrusion were similar 
as mentioned in 2.2.3.1.  To establish the transmembrane gradient, the extruded liposomes were  
separated from the unencapsulated manganese sulfate by size exclusion chromatography (SEC) 
using a Sephadex G-75 column (Sigma Aldrich, St. Louis, MO, USA)) pre-equilibrated with 
isotonic HEPES buffer (pH 7.4, 5 mM HEPES, 140 mM NaCl). DOX (0.75-3 mg/ml) dissolved 
in the same isotonic HEPES buffer was then mixed with the purified liposome suspension 
(approximately 10 mM total lipids) in 1:2 (v/v) ratio and mixture was incubated at 70˚C water 
bath for 90 min.  The cation-exchange resin Dowex® 50WX-4, 50-100 mesh (Sigma Aldrich, St. 
Louis, MO, USA) was converted to the sodium form by sequential washing with 400 ml 2 M 
NaOH per 100 g of dry resin on filter paper with a Buchner funnel.  The NaOH was removed by 
washing with 1 M NaCl until the pH returned to neutrality.  The resin was then washed several 
times with 0.9% (w/v) NaCl and dried overnight on filter paper in vacuum and stored at room 





resin = 1:60 (w/w) and shaken on an orbital shaker (Thermo Fisher Scientific, Waltham, MA) at 
approximately 100 rpm, room temperature for 25 min to remove the unencapsulated DOX from 
the DOX-loaded liposomes.  The resin was then separated from the DOX-loaded liposomes by 
filtration through glass wool in a syringe.  The resultant DOX-loaded liposome suspension 
(approximately 7 mM total lipids) was stored at 4˚C in an amber glass vial filled with argon and 
sealed with parafilm until further studies.  
2.2.4 Physicochemical characterizations of liposomes. 
2.2.4.1 Size measurement.  An aliquot (2.5-5 μL) of a liposome suspension was diluted 
in 150 μL DI water or isotonic buffer and the sizes of liposomes were measured at room 
temperature by dynamic light scattering (Zetasizer ZS90, Malvern Instruments Ltd., UK).  The 
size values are analyzed from the intensity of hydrodynamic diameters. 
2.2.4.2 Quantitation of payload DOX concentration and liposome encapsulation 
efficiency (EE).  An aliquot (10 μl) of DOX-loaded liposome suspension was lysed with 90 μL 
lysis buffer (90% (v/v) isopropanol, 0.075 M HCl) [179] in a 96-well Black Clear Bottom 
Polystyrene microplate (Corning®, NY, US),  together with 10 μL DOX standard solutions (1, 2, 
5, 10, 20, 50, 100 μg/ml) diluted in the same lysing buffer (90 μL). All samples in the 
quantitation were triplicated.  The microplates were covered with foil, and the fluorescence of 
the samples was measured at 486 nm (excitation) and 590 nm (emission) on a Synergy HT 
microplate reader (Biotek, Winooski, VT, US).  Concentration of the payload DOX of liposomes 
was estimated using a standard calibration curve from the fluorescence of the above-mentioned 
DOX standard solutions. The encapsulation efficiency (EE) of the liposomes was then calculated 
by the following formula.   
𝐸𝐸 =  
𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 𝐷𝑂𝑋 𝐶𝑜𝑛𝑐.






2.2.5 Concentrating the liposome formulations.  The DOX-loaded formulations need 
to be concentrated before testing on biological systems if their DOX concentration are not 
sufficient for the treatment.  A diafiltration column (MicroKros®, Spectrum, Stamford, CT, US) 
was used to concentrate the liposome suspension by partially removing the extra-liposomal 
buffer. The liposome suspension was slowly extruded by two syringes through the diafiltration 
column to be condensed to the needed concentration.  Typically, a 2 ml liposome suspension was 
extruded 14 times to yield a 0.5 ml concentrated formulation.   
2.3 Results and Discussions 
2.3.1 Synthesis of imidazole-based ether lipids DHI, DHMI and DHDMI.  The 
synthesis of DHG Tosylate and imidazole-based lipids were carried out to yield three pH-
sensitive convertible lipids with similar structures.  The synthesis methods were based on the 
tosyl activation of the lipid DHG and the substitution of the tosylate group with the imidazole 
moiety using mercaptoimidazole compounds.  Tosylate was known as a reliable leaving group, 
so it was used for the conjugation of lipid chains and the imidazole headgroups.  The anhydrous 
conditions were essential for the high yield of the conjugation reaction.  Besides, to purify the 
imidazole-based lipids, the mobile phases 1-5% (v/v) methanol/dichloromethane and 3/7 (v/v) 
ethyl acetate / hexane were utilized respectively, and the former led to higher yield (30%) than 
the latter (10%).   
2.3.2 Physicochemical characterization of ICL. 
2.3.2.1 Size and PDI before and after DOX-loading.  After preparation by lipidic film 
hydration, freeze-anneal-thawing and sequential extrusion through 400 nm, 200 nm and 100 nm 
polycarbonate membranes, imidazole-based convertible liposomes containing 25% DHI, DHMI 





The Polydispersity Index (PDI), a measure of the heterogeneity of the size of particles in a 
mixture, was lower than 0.3 for all the formulations.  After the sequential extrusion and before 
the loading with DOX, the mean size and PDI of the ICL are shown in Table 2.3 together with 
NSL for comparison.   
 
Table 2.3 
Size and PDI of empty ICL and NSL after sequential extrusion with 400 nm, 200 nm and 100 nm 
polycarbonate membranes and before DOX loading 
  Ext by 400 nm Ext by 200 nm Ext by 100 nm 










DHI/DSPC/DPPE-PEG 25/70/5 219.6 0.310 189.1 0.283 124.4 0.195 
DHMI/DSPC/DPPE-PEG 25/70/5 179.2 0.149 170.0 0.271 118.7 0.205 
DHDMI/DSPC/DPPE-PEG 25/70/5 176.2 0.179 146.5 0.226 105.7 0.178 
DSPC/DPPE-PEG 95/5 226.0 0.227 136.9 0.152 104.7 0.050 
Note. Size values are the cumulative intensity of hydrodynamic diameters. 
 
After the sequential extrusions, each formulation was passed through a SEC column 
(Sephadex G-75) equilibrated with the isotonic HEPES buffer (pH 7.4, 5 mM HEPES, 140 mM 
NaCl) to generate the manganese sulfate gradient (300 mM) from inside of liposomes.  Such 
liposome suspensions were then mixed with DOX in the same buffer at 1000 μg/ml final DOX 
concentration in the DOX-liposome mixture.  After 90 min incubation at 70˚C and resin removal 
of the unencapsulated DOX, the sizes of ICL and NSL significantly increased (Table 2.4).  The 
DHI/DSPC/DPPE-PEG (last extruded by 100 nm membrane) showed the most increase in the 
mean size value from 124.4 nm to 802.7 nm while DHMI/DSPC/DPPE-PEG (last extruded by 
100 nm membrane) showed the increase from 118.7 nm to 693 nm.  The mean size of the 





loading.  The non-pH-sensitive control liposome DSPC/DPPE-PEG had similar increase in mean 
size from 104.7 nm to 372.7 nm.  The liposomes last extruded by the 200 nm polycarbonate 
membrane had similar augment in size.  The PDI of each formulation also increased after the 
drug loading.   
 
Table 2.4 
Size and PDI of DOX-loaded ICL and NSL that were last extruded by 200 nm and 100 nm 
polycarbonate membranes 
  Extruded by 200 nm Extruded by 100 nm 
Lipid Compositions Mol Ratio Size (nm) PDI Size (nm) PDI 
DHI/DSPC/DPPE-PEG 25/70/5 807.6.0 0.845 802.7 0.721 
DHMI/DSPC/DPPE-PEG 25/70/5 550.0 0.644 693.0 0.605 
DHDMI/DSPC/DPPE-PEG 25/70/5 266.8 0.501 246.1 0.501 
DSPC/DPPE-PEG 95/5 401.4 0.246 372.7 0.620 
Note. Size values are the cumulative intensity of hydrodynamic diameters. 
 
The pharmacokinetics and tissue distribution of drug delivery systems are remarkably 
affected by their size [180].  For PEGylated nano-carriers, it is preferred to keep the size under 
200 nm to take advantage of the EPR effect in tumor tissues.  In this study, we developed the 
methods to prepare drug-free formulations with sizes under 200 nm, but their sizes significantly 
increase after being loaded with the payload drug DOX.  It was reported that, during drug 
loading, DOX induced aggregation of negatively charged liposomes when the temperature is 
cooled down to the liposome’s phase transition temperature (Tm) [181].  It was suggested that the 
aggregation resulted from the electrostatic interactions between the unencapsulated DOX 
molecules (positively charged) and the negatively charged lipids on the liposome surface.  It was 





another to induce the liposome aggregation.  In this study, the aggregation of our ICL and NSL 
during drug loading may also result from their electrostatic attraction with DOX.  The particle 
size of the formulations after drug loading reflected the extent of aggregation.  This speculation 
is also supported by the ζ- potential measurements of ICL and NSL at pH 6.0-7.4 (Figure 2.4), 
which showed that all the three ICL and NSL formulations carried a negative ζ- potential at pH 
7.4.  The further formulation studies in this chapter aimed to keep the size of the DOX-loaded 
formulation under 200 nm by reducing the aggregation while maintaining the pH-sensitivity.  
The resultant convertible liposomes would then serve as a viable anticancer drug delivery 
system.  
2.3.2.2 Encapsulation efficiency (EE)and DOX concentration of ICL.  After separating 
the DOX-loaded liposomes from unencapsulated DOX in the suspensions, the payload DOX 
concentration was measured (Table 2.5) and the EE was calculated from the payload DOX 
concentration and the input DOX concentration.  The EE of the formulations ranged from 40% to 
80%, depending on the lipid compositions.   
 
Table 2.5 
Encapsulation efficiency and DOX concentration of ICL and NSL that had been extruded by 200 
nm and 100 nm polycarbonate membranes 
  Extruded by 200 nm Extruded by 100 nm 
Lipid 
Compositions 
Mol Ratio EE (%) 







25/70/5 45.79±0.44 457.92±4.44 41.28±0.45 412.80±4.50 
DHMI/DSPC/
DPPE-PEG 
25/70/5 51.64±0.35 516.40±3.51 52.17±1.52 521.68±15.23 
DHDMI/DSPC
/DPPE-PEG 
25/70/5 75.54±1.00 755.44±10.07 65.55±0.65 655. 51±6.50 
DSPC/DPPE-
PEG 
95/5 62.35±0.80 623.49±8.02 52.80±0.69 527.96±6.94 






EE of liposomes is considered a very important characteristic, because higher EE would 
allow higher concentration of the payload drug to be delivered to biological systems [177].  The 
anticancer activity studies on MCS models needed 250 μg/ml or higher DOX concentration in 
the formulations.  The results in this study indicated the above formulations were capable of 
loading sufficient DOX for the later anticancer activity studies (Chapter V).  To achieve a high 
loading capacity and efficiency, the manganese sulfate gradient was applied to generate the 
transmembrane ion gradient [182], which was acknowledged as one of the well-developed 
remote loading methods.  At Tm, the membrane of liposomes became more permeable, which 
allowed the DOX molecules to diffuse into the liposome aqueous interior, wherein the 
concentration of manganese sulfate is much higher than in the extra-liposomal medium.  
Manganese formed a complex with DOX, which drove the drug loading and the drug retention in 
the liposome aqueous interior.   
2.3.2.3 Factors affecting size, PDI and EE.  To reduce the sizes of DOX-loaded ICL 
while keeping sufficient DOX encapsulation, several methods have been attempted to improve 
the formulations.  The following sections will discuss a number of formulation conditions that 
affect the ICL properties such as size, PDI and EE.  Such formulation conditions include drug 
loading time, lipid compositions, drug-loading pH, temperature mixing with resin and input 
DOX concentration.   
2.3.2.3.1 Effect of longer time of drug-loading.  To investigate the kinetic changes of size 
and EE in drug loading, an aliquot of liposome suspension was taken at different time point of 
drug loading (20, 30, 40, 50, 60, 70, 80 and 90 min) to measure its size and EE.  As shown in 
Figure 2.3 (a), the size of ICL and NSL increased with longer drug-loading time.  Compared with 





showed higher extent of aggregation, where the size increased to 200 nm after 40 min incubation 
and 500 nm after 90 min incubation.  As shown in Figure 2.3 (b), the EE of ICL and NSL 
increased with longer incubation time.  The convertible liposomes DHDMI/DSPC/DPPE-PEG 
showed the smallest size and the highest EE than the other formulations in this study, which 
suggests that the DHDMI/DSPC/DPPE-PEG formulation possesses better stability than the other 




Figure 2.3.  (a) Change of liposome sizes with incubation time in drug loading. Data presented as 
mean ± SD, N = 7. (b) Change of EE of liposomes with incubation time in drug loading. Data 
presented as mean ± SD, N = 3.  
 
The study obtained the result revealing the correlation between longer incubation time 
and larger size of DOX-loaded ICL, which suggested the size of liposomes can be decreased by 
shortened incubation time.  Nevertheless, based on the result, the aggregation of convertible DHI 







































with EE of 20% contained 200 μg/ml encapsulated DOX, which needed TFF concentrating to 
reach the concentration demanded in the cytotoxicity studies on MCS.  
2.3.2.3.2 Effect of lipid composition – C18 phospholipid versus C16 phospholipid.  To 
investigate the influence of phospholipid on DOX-loaded liposomes, liposomes consisting of 
70% C16 phospholipid DPPC (DHI/DPPC/DPPE-PEG) were prepared in comparison to 
liposomes consisting of 70% C18 phospholipid DSPC (DHI/DSPC/DPPE-PEG).  As shown in 
Table 2.6, DHI/DPPC/DPPE-PEG liposomes extruded by both 200 nm and 100 nm 
polycarbonate membranes showed dramatically larger sizes (over 2000 nm in hydrodynamic 
diameter) than the DHI/DSPC/DPPE-PEG liposomes.  Interestingly, the larger 
DHI/DPPC/DPPE-PEG liposomes carried a smaller PDI than the DHI/DPPC/DPPE-PEG 
liposomes, indicating that the DHI/DPPC/DPPE-PEG liposomes are more homogeneous than the 
DHI/DSPC/DPPE-PEG liposomes.   
 
Table 2.6 
Effect of phospholipid the on the size and PDI of DOX-loaded ICL 
  Extruded by 200 nm Extruded by 100 nm 
Lipid Compositions Mol Ratio Size (nm) PDI Size (nm) PDI 
DHI/DSPC/DPPE-PEG 25/70/5 706.3 0.833 429.0 0.788 
DHI/DPPC/DPPE-PEG 25/70/5 2355.0 0.354 2126.0 0.343 
(Note. Size values are the cumulative intensity of hydrodynamic diameters. 
 
The EE result in Table 2.7 showed that the DHI/DPPC/DPPE-PEG liposomes contained 
more payload DOX than the DHI/DSPC/DPPE-PEG liposomes, which demonstrated the higher 
extent of aggregation in DPPC-containing ICL didn’t negatively impact the EE.  The higher EE 
of DHI/DPPC/DPPE-PEG liposomes was consistent with the earlier speculation that the 





molecules in between the aggregated liposomes.  These complexed DOX molecules could not be 
removed by the ion-exchange resin, and thus would contribute to the EE.   
 
Table 2.7 
Effect of phospholipid on EE and DOX Conc. of ICL 
  Ext by 200 nm Ext by 100 nm 
Lipid 
Compositions 
Mol Ratio EE (%) 







25/70/5 40.99±0.44 409.93±4.36 46.63±0.73 466.29±7.28 
DHI/DPPC/DPP
E-PEG 
25/70/5 72.28±0.98 722.80±9.88 65.22±7.10 652.15±71.00 
Note. Data presented as mean ± SD, N = 3. 
 
2.3.2.3.3 Effect of lipid composition - 25% cholesterol.  To investigate the influence of 
cholesterol, DOX-loaded ICL liposomes containing 25% cholesterol were prepared to compare 
with the corresponding cholesterol-free liposomes.  As shown in Table 2.8, before DOX loading, 
the sizes of liposomes containing cholesterol were below 130 nm after extrusion through the 100 
nm polycarbonate membranes, similar to the cholesterol free liposomes in Table 2.8. Based on 
the PDI results in Table 2.3 and 2.8, furthermore, the PDI values of ICL with cholesterol (Table 
2.8) were all smaller than 0.1 while those of cholesterol-free ICL were all larger than 0.1, 
indicating that cholesterol improved the homogeneity of ICL.   
 
Table 2.8 
Size and PDI of liposomes consisting of 25% cholesterol after sequential extrusion through 400 
nm, 200 nm and 100 nm polycarbonate membranes and before DOX loading 
  Ext by 400 nm Ext by 200 nm Ext by 100 nm 










DHI/DSPC/DPPE-PEG/Chol 25/45/5/25 271.1 0.212 164.0 0.197 124.1 0.088 
DHMI/DSPC/DPPE-
PEG/Chol 





(Table 2.8 Continued) 
DHDMI/DSPC/DPPE-
PEG/Chol 
25/45/5/25 247.0 0.125 159.6 0.181 115.7 0.066 
DSPC/DPPE-PEG/Chol 70/5/25 217.3 0.124 172.6 0.212 120.3 0.108 
Note. Size values are the cumulative intensity of hydrodynamic diameters 
 
As shown in Table 2.9, after 90 min DOX loading, the sizes and PDI of ICL with 
cholesterol didn’t have obvious change.  The DOX-loaded cholesterol liposomes had sizes 
smaller than 150 nm and PDI below 0.3, which means no significant aggregation took place 
during the drug loading, while the EE of all the ICL liposomes with cholesterol reached above 
60%.   
 
Table 2.9 
Size, PDI and EE of ICL liposomes containing 25% cholesterol after extrusion by 100 nm 
polycarbonate membrane and DOX-loading 
Lipid Compositions Mol Ratio Size (nm) PDI EE (%) 
DHI/DSPC/DPPE-PEG/Chol 25/45/5/25 133.6 0.145 71.38±0.61 
DHMI/DSPC/DPPE-PEG/Chol 25/45/5/25 120.0 0.075 89.86±1.27 
DHDMI/DSPC/DPPE-PEG/Chol 25/45/5/25 120.7 0.115 92.97±1.10 
DSPC/DPPE-PEG/Chol 70/5/25 144.1 0.266 60.98±1.66 
Note. Size values are the cumulative intensity of hydrodynamic diameters. EE data presented as 
mean ± SD, N = 3. 
 
Compared with DOX-loaded cholesterol free ICL and NSL, the DOX-loaded ICL and 
NSL containing 25% cholesterol showed significantly smaller sizes and higher EE.  Thus, the 







Figure 2.4.  Effect of cholesterol on sizes and EE of ICL and SNL. (a) Sizes of liposomes with and 
without 25% cholesterol. Data presented as mean ± SD, N = 7. *** p < 0.001. (b) EE of liposomes 
with and without 25% cholesterol. Data presented as mean ± SD, N = 3. ** p < 0.01, *** p < 0.001.  
 
It was reported that incorporation of cholesterol into the lipid bilayer structure can 
improve the stability of liposomal formulations [183, 184].  At T > Tm, the lipid bilayer was in 
fluid phase, in which the lipid molecules were restrained to the surface of membranes but 
nonetheless free to diffuse within this surface. Each lipid molecule had the process of random 
walk to exchange locations with its neighboring lipid molecules.  Due to its unique 
physicochemical characteristics, cholesterol helps the lipid bilayers exert their thermodynamic 
properties.  The hydrophilic domain of cholesterol molecule is little (a single hydroxyl group), 
which makes it barely resemble phospholipids.  The addition of cholesterol was found to help 
control the mobility of lipid bilayers in fluid phase and to reduce their permeability to water 
[185, 186].  Cholesterol was found to reduce the fluidity of lipid bilayers and to increase their 
mechanical rigidity by intercalating between phospholipids and filling in the cavities to decrease 
the flexibility of hydrocarbon chains of the surrounding phospholipids [187].  Furthermore, the 
inhibition of lipid mobility also reduced the lateral diffusion coefficient of lipid bilayers in fluid 





structures when the temperature was elevated above Tm.  Conversely, the addition of cholesterol 
was also found to interfere with phospholipid bilayers in gel phase by disrupting the local 
packing order of their lattice structures.  This interaction increased the diffusion coefficient and 
decreased the elastic modulus of lipid bilayers in the gel phase [188].  
In this study, liposomes were incubated with DOX at 70˚C (T > Tm) for 90 min, and a 
protective effect of cholesterol against aggregation was observed while the temperature cooled 
down.  The above-mentioned studies on cholesterol suggest that on the one hand, cholesterol 
would stabilize the fluid state of the liposome bilayers, which would increase the drug retention 
of liposomes during drug-loading, while one the other hand, cholesterol would mobilize the 
lipids in the bilayers at the gel state bilayers to hinder the aggregation from liposome-DOX-
liposome stacking.  The addition of cholesterol remarkably improved the size and EE.  
Therefore, ICL containing no cholesterol and 25% cholesterol were subjected to further studies 
to test their pH-sensitivity, stability and anticancer activity in vitro.  
2.3.2.3.4 Effect of pH during drug loading.  To explore the effect of drug loading pH on 
size and EE of DOX-loaded liposomes, liposomes with or without 25% cholesterol were 
prepared and loaded with DOX at pH 7.4 or 8.0.  As shown in Table 2.10, for both 
DHI/DSPC/DPPE-PEG and DSPC/DPPE-PEG, the sizes after DOX loading at pH 8.0 were 
dramatically larger than pH 7.4, together with smaller PDI and higher EE.  This implies that 
loading DOX at pH 8.0 induced higher percentage of aggregated liposomes than at pH 7.4, 
similar as the higher extent of aggregation observed in ICL and NSL consisting of DPPC (Table 
2.6 and 2.7).  For the liposomes consisting of 25% cholesterol, DOX loading at pH 8.0 also 
yielded larger liposomes than pH 7.4 but the size increase is not as large as liposomes without 







Effect by loading pH. Size, PDI and EE of liposomes loading DOX at pH 7.4 and 8.0 
Lipid Compositions Mol Ratio Loading pH 
Size 
(nm) 
PDI EE (%) 
DHI/DSPC/DPPE-PEG 25/70/5 7.4 808.3 0.857 40.56±4.54 
DHI/DSPC/DPPE-PEG 25/70/5 8.0 3260.0 0.643 65.97±1.15 
DSPC/DPPE-PEG 95/5 7.4 304.2 1.000 36.69±0.53 
DSPC/DPPE-PEG 95/5 8.0 1842.0 0.448 65.61±1.00 
DHI/DSPC/DPPE-PEG/Chol 25/45/5/25 7.4 159.9 0.105 91.27±1.97 
DHI/DSPC/DPPE-PEG/Chol 25/45/5/25 8.0 208.0 0.278 84.48±2.31 
DSPC/DPPE-PEG/Chol 70/5/25 7.4 148.4 0.293 52.95±0.95 
DSPC/DPPE-PEG/Chol 70/5/25 8.0 361.0 0.592 69.76±1.58 
Note. Size values are the cumulative intensity of hydrodynamic diameters. EE data presented as 
mean ± SD, N = 3. 
 
Based on this result, DOX-loading pH considerably affects the sizes of ICL liposomes.  
The addition of cholesterol restrained the interaction between liposomes and DOX at both pH 7.4 
and 8.0.  For the liposomes with cholesterol loading at pH 8.0, the slightly increase of sizes was 
the composite outcome of aggregation intensified by the elevated pH and protection effort by 
cholesterol.  
2.3.2.3.5 Effect of the temperature for mixing with resin to remove unencapsulated DOX.  
It was reported that under certain conditions, liposomes can aggregate in the gel phase but not in 
fluid phase [181].  In our studies, the ICL aggregated during the cooling down process after 
incubation with DOX at T > Tm.  To confirm this, size of NSL was measured at 70˚C 
immediately after 90 min incubation with DOX at 70˚C before cooling down and compared with 
the size of NSL measured at room temperature after cooling down.  As shown in Table 2.11, the 





smaller than the cooled downed NSL.  The detailed dynamic light scattering result of the size of 
NSL after cooling showed a peak of above 1000 nm size, which confirmed aggregation.  In 
comparison, NSL before cooling down, only showed peaks of sizes similar to or smaller than the 
cumulative size.  These data confirmed that NSL aggregated when the liposomes were cooled 
down and turned into gel phase.   
 
Table 2.11 
Cumulative size and intensity of each peak of DOX-loaded liposomes measured at 70˚C 














DSPC/DPPE-PEG 95/5 70 241.1 0.361 234.3 60.23 
DSPC/DPPE-PEG 95/5 RT 486.5 1.000 1465.0 121.0 
Note. Cumulative size values are the cumulative intensity of hydrodynamic diameters. 
 
Based on the above observation, the DOX-loaded liposomes was mixed with resin at T > 
Tm to remove unencapsulated DOX from liposome before the liposomes were cooled down to 
form the gel phase in an effort to reduce the aggregation.  As shown in Table 2.12, the liposomes 
that were mixed with resin at 50˚C had similar average size as those that were mixed with resin 
at room temperature, while the liposomes mixed with resin at 60˚C and 70˚C had slightly smaller 
average size than  at room temperature.  The peak 1 (largest peak) of the size measurement of the 
liposome mixed with resin at 60˚C and 70˚C showed more evident decrease in the diameter from 
that at room temperature compared with liposomes after drug-loading at 50˚C.  The EE of 
liposomes after being mixed with resin at 60˚C and 70˚C were lower than at room temperature 
and 50˚C, which was probably caused by less stacking of DOX on liposomes in fluid phase at 





Because the percentage of aggregated liposome was reduced after mixing the liposomes 
with resin at T ≥ Tm, filtration was attempted to remove the large liposome-DOX aggregates to 
further reduce the formulation size.  The liposome suspensions were filtered with nylon syringe 
filters of 400 nm pore.  As shown in Table 2.12, the cumulative size of liposomes after mixing 
with resin at different temperature and filtration were decreased below 150 nm.  The PDI also 
decreased considerably, which indicated the aggregated liposomes were removed.  However, the 
filtration significantly decreased the EE and the filtered liposomes suspension became more 
transparent, indicating that a substantial portion of the liposomes were trapped in the syringe 
filters.  EE for the liposomes that were mixed with resin at 60˚C or 70˚C followed by filtration 
were higher than those that were mixed with resin at 50˚C or room temperature, which is in line 
with the results that their extent of aggregation is lower (Table 2.12).  
 
Table 2.12 
Size and EE of DOX-loaded liposomes after being mixed with resin at room temperature, 50˚C, 




















× 486.5 1.000 1465.0 121.0 53.01±0.47 




× 493.5 0.605 1240.0 118.1 48.23±0.47 




× 348.8 0.647 680.6 135.4 28.47±0.60 




× 428.1 0.684 639.0 118.1 31.17±0.30 






× 455.4 0.661 1152.0 139.5 44.36±1.23 











× 427.0 0.719 724.0 76.08 46.43±0.66 
√ 125.6 0.370 95.66 256.9 5.01±0.05 
Note. Cumulative size values are the cumulative intensity of hydrodynamic diameters. EE data 
presented as mean ± SD, N = 3. 
 
The above results indicated mixing liposomes with resin at T ≥ Tm moderated the 
aggregating of liposomes but did not sufficiently decrease the average sizes of the formulations.  
The Dowex 50WX-4 was known as a cationic ion-exchange resin which bounds with the 
unencapsulated DOX and yet leave the DOX molecules that are entrapped by liposome [179].  
The result that resin partially diminished the aggregation was in line with the finding that the 
stacking of DOX and their binding with liposomes can cause aggregation.  In this study, the resin 
appeared to have limited capability in removing DOX that were stacked on the surface of 
liposomes.  Adding resin into the liposome suspension at Tm or even higher temperature only 
moderated the aggregation but did not totally prevent it.   
The filtration method was commonly used to sterilize liposomal formulations in 
industrial manufacturing [189, 190].  Our study indicate that the filtration method can cause 
considerable loss of the liposomes when the sample contains liposome aggregates of too large 
size (diameter larger than 500 nm).   
2.3.2.3.6 Effect of input DOX concentration.  To study the effect of input DOX 
concentration on size and EE of liposomes, liposomes were mixed with 1000, 500, 250 μg/ml 
DOX solutions and incubated for 90 min of drug loading.  As can be seen in Figure 2.5 (a), the 
sizes of liposomes decreased after incubation with lower and lower DOX concentration, which 
was consistent with the prior report that the aggregation resulted from stacking of DOX and their 





liposomes that were incubated with different concentrations of input DOX.  Because the input 
DOX concentration was reduced, the encapsulated DOX concentration was further considered as 
a characteristic of the drug loading, in consideration that the minimum concentration of the DOX 
concentration for anticancer studies in MCS models.  Although the lower input DOX decreased 
the liposome size, the encapsulated DOX concentration of the resultant DHI and NSL liposomes 
also dropped below 200 μg/ml, which is required for MCS studies.  Therefore, the resultant 
formulations were concentrated with a diafiltration column.  After extrusion through the 
diafiltration column for 14 times, the volume of each liposome suspension was reduced from 2 
mL to 0.5 mL while the encapsulated DOX concentration was raised above 300 μg/ml for further 
anticancer investigations in MCS.  
 
 
Figure 2.5.  Effect of input DOX concentration on sizes and EE of ICL and SNL. (a) Sizes of 
liposomes after DOX loading at different input concentrations. Data presented as mean ± SD, N = 
7. *** p < 0.001. (b) EE and encapsulated DOX concentration of liposomes after DOX loading at 


































































Based on the results in Table 2.4 and Figure 2.3 (a), the ICL consisting of DHI was more 
prone to aggregation during drug loading than ICL consisting of DHMI or DHDMI.  Drug 
loading at a lower DOX concentration of 200 μg/ml yielded smaller ICL consisting of DHI 
(198.8 nm in diameter) and NSL (121.2 nm in diameter), indicating that the input DOX 
concentration during drug loading was a significant factor to influence the sizes of DOX-loaded 
ICL and NSL.  With such method, ICL formulations containing DHI, DHMI and DHDMI were 
prepared and characterized with sizes around or below 200 nm (Table 2.13). TFF concentrating 
was needed for those formulations before applied in MCS treatment.  
 
Table 2.13 
Size, PDI and EE of ICL liposomes lasted extruded by 100 nm polycarbonate membrane and 
loaded with 200 μg/ml DOX for 90min.  
Lipid Compositions Mol Ratio Size (nm) PDI EE (%) 
DHI/DSPC/DPPE-PEG 25/70/5 198.8 0.531 56.62±2.06 
DHMI/DSPC/DPPE-PEG 25/70/5 179.6 0.573 53.18±1.12 
DHDMI/DSPC/DPPE-PEG 25/70/5 202.9 0.115 59.54±0.59 
DSPC/DPPE-PEG 95/5 121.2 0.266 57.74±0.98 
Note. Size values are the cumulative intensity of hydrodynamic diameters. EE data presented as 
mean ± SD, N = 3. 
 
2.4 Summary 
The imidazole-based ether lipids DHI, DHMI and DHDMI were successfully 
synthesized.  Using film hydration, freeze-anneal-thawing and extrusion methods, ICL were 
successfully prepared with sizes smaller than 130 nm and PDI under 0.3.  With manganese 
sulfate gradient method at the input DOX concentration of 1000 μg/ml, ICL were loaded with 





during DOX-loading due to aggregation.  Factors influencing the sizes and EE of ICL were 
studied to improve the ICL formulations, including drug loading time, length of acyl chains of 
phospholipids, addition of cholesterol, drug-loading pH, temperature of mixing with the resin 
and input DOX concentration.  Reducing drug loading time, adding cholesterol, mixing with 
resin at T ≥ Tm followed with filtration and reducing the input DOX concentration decreased the 
sizes of DOX-loaded ICL by inhibiting or preventing the liposome aggregation.  Among these 
methods, adding 25% cholesterol and reducing the input DOX concentration from 1000 μg/ml 
into 200 μg/ml most effectively decreased the sizes of DOX-loaded ICL to about 200 nm in 
diameter without dramatically reducing EE.  The advantages and disadvantages of these 
improvement methods are summarized in Table 2.13.  
 
Table 2.14 
Comparison of methods to improve the size and EE of DOX-loaded ICL 
Methods Pros Cons 
Reducing drug loading time Size ~200 nm Lowered EE 
Incorporation with cholesterol Size ~140 nm, EE ~70%  
Mixing with resin at T ≥ Tm 
and filtration 
Size ~120 nm Lowered EE 
Reducing input DOX Conc. Size ~200 nm Lowered DOX Conc. 
 
The addition of cholesterol seems to be the most effective method to improve the size and 
EE.  However, modified composition of ICL formulations could also impact their pH-sensitivity.  
Thus, pH-sensitivity studies were carried out on both the cholesterol-free ICL and the ICL 









A pH-sensitive liposome is a modified form of liposomes that shows high stability at 
physiological pH (pH 7.4) while undergoing destabilization or physicochemical changes under 
acidic conditions [23].  pH-sensitive liposomes can serve as viable drug delivery systems 
because many physiological and pathological scenarios involve acidic pH, including 
endosomal/lysosomal vesicles solid tumors and sites of inflammation [23, 114].  The 
composition of the imidazole-based convertible liposomes was designed to protonate in response 
to the acidic extracellular pH in tumor (pH 6.0-7.0).  The protonated imidazole lipids would then 
interact with the negatively charged DPPE-PEG on the liposome membrane to condense them 
laterally and thus to unveil the excessive positive charges on the surface of ICL.  Such pH-
triggered ICL would in turn have stronger electrostatic interaction with cancer cells and/or 
release more of the payload drug.  
Based on the results of Chapter II, two methods were discovered to considerably improve 
the physicochemical properties of ICL: reduction of input DOX concentration during drug 
loading and addition of cholesterol in lipid composition.  Studies in this chapter aim to test the 
pH-sensitivity of ICL by exposing them to aqueous solutions of pH 6.0-7.4 in vitro.  Based on 
the aforementioned properties of ICL, the pH-sensitivity studies include pH-dependent change of 
liposome surface charge (-potential) and  pH-dependent DOX release, which would test ICL’s 
potential to interact more with negatively charged cells and to release more payload drug at 






3.1.1 Calculated pKa of the imidazole-based ether lipids.  The pKa of the imidazole-
based ether lipids DHI, DHMI and DHDMI were calculated using ACD/pKa DB software 
(Advanced Chemistry Development, Inc., Ontario, Canada) [191].  Calculation by software was 
chosen instead of experimental methods for pKa determination of imidazole-based lipids due to 
the assembly of these lipids in aqueous solutions, which makes it hard to trace the protonation 
status of each lipid molecule in water.  The calculated pKa values of the imidazole-based lipids 
are evaluated together with the ζ- potentials measurements of ICL liposomes containing these 
lipids to assess the protonation of these lipids in response to different pH.  As shown in Table 3.1, 
the estimated pKa of the imidazole-based lipids ranges from 5.36 to 6.75.  As a lipid with a basic 
headgroup, each imidazole-based lipid would protonate more in an acidic environment than 




Calculated pKa of DHI, DHMI and DHDMI using ACD/pKa DB software. [129] 





3.1.2 Phase separation of ICL in response to acidic pH.  Due to the significantly strong 
electrostatic interaction between the imidazole-based lipids and DPPE-PEG, phase separation 
was observed in the ICL bilayer at acidic pH, which was reported in our prior studies [129].  The 
liposome membrane can separate into multiple phases when interaction between its lipid 





monitored by differential scanning calorimetry (DSC), a thermoanalytical technique developed in 
1962 [193].  DSC measures the heat a sample absorbs to increase its temperature (aka, heat 
capacity) as a function of temperature.  Therefore, DSC can attest to lipid phase separation by 
recording multiple peaks of higher heat capacities that are generated from the gel-to-liquid 
transition of the separated lipid phases at different temperatures (Figure 3.1).  The DSC 
thermogram of the convertible liposome DHI/DSPC/DPPE-PEG (Figure 3.2) in prior studies of 
our group showed a single broad peak at pH 7.4 between 56˚C and 65˚C, which indicated the 
gel-to-liquid transition of only one phase and therefore the homogeneous mixing of the lipid 
components of ICL (DSPC (C18), DPPE-PEG(C16) and imidazole-based lipids (C16)) at pH 7.4.  
At pH 6.0, the DSC thermogram showed an additional broad peak at around 52 ˚C (Figure 3.1), 
which indicated the formation of at least two lipid phases on the liposome membrane.  The new 
lipid phase was probably rich in DSPC because liposomes of only DSPC has a very similar gel-
to-liquid phase transition temperature of 54˚C.  The newly formed lipid phase on the liposomes 
supports our proposed mechanism of the pH-sensitivity, where interaction between the 
protonated imidazole-based lipids and the negatively charged DPPE-PEG would expulsed the 







(Figure 3.1 Continued) 
Figure 3.1.  DSC Thermogram of DSPC. [194] 
 
 
Figure 3.2.  DSC Thermogram of Convertible Liposome I (DHI/DSPC/DPPE-PEG) at pH 7.4 and 
6.0. [129] 
 
The acidic pH-triggered phase separation of DOX-loaded ICL would enhance the 
anticancer activity in bio-systems.  Firstly, the clustering of negatively charged PEGylated lipids 
expulsed DSPC doped with positively charged imidazole lipids to form a domain displaying 
positive charges.  This domain would not only have excess positive charges, but also would be 
cleared from steric hindrance of PEG, both of which would strengthen its electrostatic interaction 
with negatively charged cell surface.  Furthermore, the fractures of the liposome membrane 
between the DPPE-PEG-rich phase and the DSPC-rich phase would be more permeable to 
diffusion, which would enhance drug release at acidic pH.  
3.2 Materials and Methods 
3.2.1 Materials.  2-[4-(2-hydroxyethyl)piperazin-1-yl]-ethanesulfonic acid (HEPES) and 
2-(N-morpholino)ethanesulfonic acid (MES) were purchased from Fisher Scientific (Hampton, 




















Convertible Liposome I pH 7.4





snglycero-3-phosphoethanolamine-N-[azido(polyethylene glycol)-2000 (DPPE-PEG (2000)), 1-
palmitoyl-2-oleoyl-glycero-3 phosphocholine (POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphoethanolamine (POPE), 1-palmitoyl-2-oleoyl-sn-glycero-3 phospho-L-serine (sodium 
salt) (POPS) and L-α-phosphatidylinositol (Soy) (L-R-PI) were purchased from Avanti Polar 
Lipids, Inc. (Alabaster, AL, USA).  Cholesterol, Dowex® 50WX-4 (50-100 mesh), Sephadex G-
25 were purchased from Sigma-Aldrich (St. Louis, MO, USA).  Doxorubicin Hydrochloride was 
purchased from Biotang (Waltham, MA, USA).  All other organic solvents and chemicals were 
purchased from Sigma Aldrich, Fisher Scientific or VWR.   
3.2.2 pH-triggered acquisition of positive charges by ICL.  The ζ- potential of ICL and 
the mean sizes of ICL mixed with equimolar model liposomes at pH 6.0, 6.5, 7.0 7.4 were 
measured to monitor the pH-triggered acquisition of positive charges by ICL.   
3.2.2.1 ζ- potential measurement at pH 6.0, 6.5, 7.0, 7.4.  In order to enhance the 
detection of changes in liposome surface charge, ICL and NSL were prepared by hydration in an 
isotone buffer of low ionic strength (pH 7.4, 5 mM HEPES, 5% (w/v) Glucose) [195].  The 
liposome preparation methods were similar as in 2.2.2.1.  An aliquot (50-100 μL) of the resultant 
suspension of ICL or NSL was diluted in 900 μL isotonic MES buffer (pH 6.0 and 6.5, 10 mM 
MES, 5% (w/v) Glucose) and isotonic HEPES buffer (pH 7.0 and 7.4, 10 mM HEPES, 5% (w/v) 
Glucose), and the ζ- potentials was measured at 37˚C based on electrophoresis mobility under 
applied voltage (Zetasizer ZS90, Malvern Instruments Ltd., UK). 
3.2.2.2 Interaction of ICL with model liposomes.  The model liposomes [196, 197] 
mimicking the lipid composition of biomembranes were prepared using film hydration, freeze-
thawing and extrusion.  Briefly, a chloroform solution of POPC: POPE: POPS: L-R-PI: 





to form a lipidic film on a Buchi rotavapor at room temperature.  The lipidic film was further 
dried in vacuum oven for over 4 hours at room temperature to remove the residual of solvent 
completely.  The lipidic film was then hydrated with isotonic HEPES buffer (pH 7.4, 5 mM 
HEPES, 140 mM NaCl) by intermittent agitation to obtain a liposomes suspension containing 20 
mM total lipids.  The flask was filled with argon and sealed with parafilm.  The Liposome 
suspension was freeze-thawed by rapidly freezing in liquid nitrogen, emerging in ice-water 
mixture for 2 min and thawing in water at room temperature for 5 min.  The freeze-anneal-
thawing was repeated for 11 times.  The liposome suspension was extruded 11 times though 400 
nm polycarbonate membranes (Nucleopore Corp., Pleasanton, CA, US) at room temperature 
using a handling Mini-extruder (Avanti Polar Lipids Inc., Alabaster, AL).  The mean size of the 
resultant model liposomes was 192.7 nm in diameter as measured by Zetasizer ZS90.  Liposome 
suspension of ICL and NSL were mixed with the model liposome containing equimolar total 
lipid and 5 μL of the mixture was diluted in 150 μL isotonic MES buffer (pH 6.0 and 6.5, 10 mM 
MES, 140 mM NaCl) and isotonic HEPES buffer (pH 7.0 and 7.4, 10 mM HEPES, 140 mM 
NaCl).  The size of the particles in the diluted mixtures was measured at 37˚C by dynamic light 
scattering (Zetasizer ZS90, Malvern Instruments Ltd., UK).  
3.2.3 pH-triggered drug release of ICL. 
3.2.3.1 Qualification of initial DOX Concentration in liposomes diluted with buffers at 
pH 6.0, 6.5, 7.0, 7.4.  Liposome formulation (100 L) was severally diluted with 500 μL MES 
buffer (pH 6.0 and 6.5, 100 mM MES, 1.7% (w/v) Glucose) and HEPES buffer (pH 7.0 and 7.4, 
100 mM HEPES, 1.7% (w/v) Glucose) in 1.5 mL Amber glass vials.  An aliquot (10 μL) of each 
diluted sample was immediately lysed with 90 μL lysing buffer (90% (v/v) isopropanol, 0.075 M 





initial DOX concentration Ci (as at time point 0 hour) was qualified with a standard calibration 
curve generated from the standard DOX solutions as mentioned in 2.2.4.  All samples in 96-well 
microplate were triplicated. The microplates with samples were covered with foil before reading. 
3.2.3.2 pH-triggered drug release from liposomes determined by direct resin 
adsorption.  The liposome samples diluted by buffer at different pH (6.0, 6.5, 7.0, 7.4) as in 
2.2.5.1 were mixed with cation-exchange resin Dowex® 50WX-4 (50-100 mesh) at DOX: resin 
= 1:200 (w/w) ratio.  The mixtures were incubated and gently shaken in an incubator at 37˚C. An 
aliquot (10 μL) of supernatant was taken from each sample at time points 1, 3, 6, 12, 24, 48 
hours to be lysed with 90 μL lysing buffer (90% (v/v) isopropanol, 0.075 M HCl) in a 96-well 
Black Clear Bottom Polystyrene microplate(Corning®, NY, US).  The DOX concentration of 
supernatant Cs, which is the concentration of DOX retained in liposome was qualified by 
fluorescent spectrometry using a standard calibration curve generated from the standard DOX 
solutions as mentioned in 2.2.4.  All samples in 96-well microplate were triplicated.  The 
microplates with samples before recording were covered with foil. The percentage of released 
DOX was determined by the following equation,  
% 𝑅𝑒𝑙𝑒𝑎𝑠𝑒𝑑 𝐷𝑂𝑋 = (1 −
𝐶𝑠
𝐶𝑖
) × 100%  
Where Cs = concentration of DOX retained in liposome after resin absorption, Ci = initial 
liposomal DOX concentration.  
3.3 Results and Discussions 
3.3.1 pH-triggered acquisition of positive charges by ICL. 
3.3.1.1 Acidic pH-triggered elevation of ζ- potentials of ICL.  ζ- potentials of drug-free 
ICL and NSL at pH 6.0, 6.5, 7.0, and 7.4, at 37˚C were measured to evaluate the pH-sensitivity 





DHDMI) showed significant increase of ζ- potential when pH was adjusted from 7.4 to 6.0.  
Particularly, the ICL containing DHMI and DHDMI were converted to possess positive surface 
charges at pH 6.0.  The extent of the ζ- potential increase of ICL was correlated with the pKa of 
their imidazole-based lipids (pKa: DHDMI > DHMI > DHI).  This result demonstrated that the 
pH-sensitivity of ICL was rendered by the protonation of the imidazole-based lipids DHI, DHMI 
and DHDMI.  By contrast, the NSL (DSPC/DPPE-PEG) displayed negative ζ- potentials below -
10 mV at both physiology and acidic pH.  However, as can be seen in Figure 3.3 (b), the three 
ICL containing 25% cholesterol didn’t show noticeable rise of ζ- potentials at any of the pH 
under this study but instead fluctuated between -5 mV and -20 mV.  This result indicated that the 
pH-sensitivity of ICL, as displayed by the acidic pH-triggered acquisition of positive surface 




Figure 3.3.  ζ- potential of ICL without (a) or with (b) 25% cholesterol at 37 ℃, pH 6.0, 6.5, 7.0, 























































3.3.1.2 Acidic pH-triggered interaction between ICL and model liposome.  The acidic 
pH-triggered interaction of ICL with model liposomes was characterized based on prior studies 
in our group [129].  The negatively charged model liposomes, utilized as a simple and fast model 
to simulate the components and electrostatic property of biomembranes, were successfully 
prepared as shown in Table 3.2.   
 
Table 3.2 
Size, PDI and ζ- potential of model liposomes 
Lipid Compositions Mol Ratio Size (nm) PDI ζ- potential (mV) 
POPC/POPE/POPS/L-R-PI/Chol 50/20/5/10/15 192.7 0.180 -51.77±1.18 
 
The stock preparation of the model liposomes was diluted in isotonic buffer at pH 6.0, 
6.5, 7.0 and 7.4, and then mixed with equimolar drug-free ICL and NSL.  The particle size of the 
mixture was measured at 37℃.  As shown in Figure 3.4 (a), the DHDMI/DSPC/DPPE-PEG 
showed remarkable increase of the cumulative size at pH 6.0 compared with pH 7.4.  The size 
increase indicated the aggregation between ICL and model liposomes due to the electrostatic 
interaction.  By contrast, as shown in Figure 3.4 (b), the mixture of model liposomes and ICL 
consisting of cholesterol did not show noticeable size increase, which indicated no aggregation 







Figure 3.4.   (a) Mean sizes of equimolar mixture of model liposome and DHDMI/DSPC/DPPE-
PEG at pH 6.0, 6.5, 7.0, and 7.4. Data presented as mean ± SD, N = 3. (b) Mean size of 
equimolar mixture of model liposome and liposome containing cholesterol at pH 6.0, 6.5, 7.0, 
and 7.4. Data presented as mean ± SD, N = 3. 
 
Based on the results in 3.3.1, the introduction of imidazole-based convertible lipids 
introduced pH-sensitivity to liposomes, while the addition of cholesterol was found to suppress 
the pH-sensitivity.  As directly displayed by the pH-triggered rise of ζ- potentials and further 
supported by the pH-triggered interaction with model liposomes, the cholesterol-free ICL were 
negatively charged at pH 7.4 and yet converted to cationic liposomes at acidic pH, while the ICL 
containing cholesterol showed negative surface charges at both pH 7.4 and acidic pH.  As 
discussed in 2.3.2.3.3, cholesterol was reported to help stabilize the fluid phase bilayer structures 
of liposomes by inserting into cavities between phospholipids to control the flexibility of the 
hydrocarbon chains.  However, at T < Tm, incorporation of cholesterol obstructed the movements 



















































the multibody interaction between cholesterol and phospholipid headgroups in phospholipid 
bilayers containing cholesterol [192, 198].  Even though cholesterol has a high solubility in 
phospholipids (about 67 mol % at saturation for many types of PC), the cholesterol molecules are 
prone to tie up their neighboring phospholipids to accommodate in a lattice structure that is 
stable in water [192].  In a bilayer structure, the nonpolar cholesterols must be covered by polar 
phospholipid headgroups to minimize its thermodynamically unfavorable exposure to water at 
the membrane-water interface.  Such required coverage substantially limits the lateral diffusion 
of the lipids compared to the corresponding cholesterol-free bilayers.  Furthermore, it was also 
demonstrated that as phospholipid headgroups cover cholesterol to form the “umbrella”, the 
hydrophobicity of the liposome membrane increases, which further reduces its affinity with 
cations [199].  
This “umbrella model” is consistent with the results in our studies.  The distinct display 
of surface positive charges by ICL would need not only protonation of the imidazole-based lipids 
but also the phase separation that was implemented by the lateral redistribution and assembly of 
negatively charged DPPE-PEG and positively charged imidazole-based lipids.  In our study, the 
pH-sensitivity was recorded in conditions at 37˚C, which is below the Tm of ICL (estimated 
63˚C).  Therefore, based on the “umbrella model”, DPPE-PEG and imidazole-based lipids would 
not be able to cluster at acidic pH when cholesterol prohibits the lipid lateral redistribution by 
tying up the surrounding phospholipids.  Furthermore, the addition of cholesterol increases the 
hydrophobicity of the liposome membrane, which would reduce its affinity with protons, and 
thus reduce the protonation of imidazole-based lipids.  Such speculation is supported by the 
observation that ICL with cholesterol maintained negative a -potentials at acidic pH.  In our 





physicochemical properties of DOX-loaded ICL.  However, the inhibition of the lipid lateral 
diffusion by cholesterol at T < Tm also inhibited the pH-triggered display of positive charges by 
ICL.  Therefore, further drug release and cytotoxicity studies were carried out to evaluate ICL 
with and without cholesterol.   
3.3.2 pH-triggered drug release of ICL.  Drug release studies were carried out to 
further test the stability and pH-sensitivity of ICL without or with cholesterol.  After extrusion by 
200 nm and 100 nm polycarbonate membrane, ICL without or with cholesterol were loaded with 
DOX and then incubated at 37˚C, pH 6.0, 6.5, 7.0, and 7.4  for 12 hours, and the change of 
fluorescence of DOX was recorded to calculate the drug release.  As shown in Figure 3.5, the 
DHI, DHMI, DHDMI and NSL liposomes without cholesterol released 62.91±7.15%, 
47.15±4.98%, 19.02±3.27% and 24.15±1.28%, respectively, of the encapsulated DOX after 
incubation at pH 7.4 for 12 hours, which indicated that the stability of DHDMI and NSL 
liposomes were higher than DHI and DHDMI liposomes at the physiological pH 7.4 
environment.  Figure 3.5 (b) showed the DHMI liposomes released more DOX at pH 6.0 than 
other higher pH, which again illustrated that the DHMI formulation was sensitive to the acidic 
pH.  According to Figure 3.5 (c) and (d), the DHDMI and NSL liposomes showed no evident low 
pH-triggered increase in drug release.  Figure 3.5 (a) showed the DHI liposomes released more 
DOX at pH 6.0 than pH 6.5 and 7.0 but not more than pH 7.4, which might be due to its 








Figure 3.5. The percentage of DOX release from liposomes extruded by 200 nm over 12 hours at 
37 ℃, pH 6.0, 6.5, 7.0, 7.4. Data presented as mean ± SD, N = 3.  
 
As shown in Figure 3.6, for cholesterol-free liposomes that had been extruded by 100 nm 
polycarbonate membrane, the DHI, DHMI, DHDMI and NSL liposomes incubated released 
64.53±1.74%, 53.65±2.27%, 20.36±0.83% and 29.56±0.70% DOX in 12 hours at pH 7.4, which 
was in consistence with the formulations extruded by 200 nm.  Specifically, Figure 3.6 (b) 











































































(c) DHDMI/DSPC/DPPE-PEG - 200 nm 






























pH.  However, Figure 3.6 (a) (c) and (d) showed no obvious acidic pH-triggered enhancement of 
drug release from DHI, DHDMI and NSL liposomes. 
 
 
Figure 3.6.  The percentage of released DOX of liposomes extruded by 100 nm over 12 hours of 
incubation at 37 ℃, pH 6.0, 6.5, 7.0, and 7.4. Data presented as mean ± SD, N = 3.  
 
As shown in Figure 3.7, after incorporation of 25% cholesterol and extrusion through 100 

























(c) DHDMI/DSPC/DPPE-PEG - 100 nm
















































































56.19±0.78%, 47.11±0.60%, 40.32±0.99% and 57.70±3.03% DOX, respectively after incubation 
at pH 7.4 for 12 hours.  Compared with the cholesterol-free counterparts, the DHI and DHMI 
liposomes with cholesterol showed similar level of drug release, while the DHDMI and NSL 
liposomes with cholesterol showed increased drug release.  None of the formulation with 
cholesterol showed pH-triggered enhancement in drug release, which indicates that the addition 
















































































Chol - 100 nm































(Figure 3.7 Continued) 
Figure 3.7.  Release of DOX from liposomes consisting of 25% cholesterol and extruded by 100 
nm over 12 hours of incubation at 37 ℃, pH 6.0, 6.5, 7.0, and 7.4. Data presented as mean ± SD, 
N = 3.  
 
In the drug release study, the stability (presented as drug retention at physiology pH 7.4) 
and pH-sensitivity of ICL and NSL at 37℃ were characterized, and the effect of cholesterol 
incorporation was investigated.  In this study, the cholesterol-free ICL containing DHMI showed 
pH-triggered increase of drug release, which would favor its anticancer activity in the acidic 
tumor microenvironment. The ICL consisting of DHI showed some enhanced drug release 
however also released substantial percentage of the drug at pH 7.4, which suggests that DHI ICL 
are less stable than DHMI ICL.  The drug release of DHDMI and NSL liposomes showed no 
sensitivity to acidic pH but better stability than DHI and DHMI liposomes at pH 7.4, 37℃. The 
sensitivity to acidic pH in the drug release study could be explained by the phase separation of 
ICL at acidic pH, which resulted in destabilization of liposomes.  It was reported the release of 
content entrapped in liposomes was the consequence of accelerated diffusion through the 
liposomal membranes [200].  The release of content would occur when liposomes lose some or 
all of their membrane integrity, thus leaking out some or all of the entrapped content to the 
external media over time.  The stability of liposomes was reported to be correlated with the 
length of acyl chains of lipids [177].  The release kinetics can be controlled by the addition of 
different lipid components possessing different Tm, because the lateral diffusion coefficient 
depends on lipid packing and acyl chain ordering [201].  The liposomes containing 
phospholipids with longer acyl chains would have a higher Tm and higher stability.  In our study, 
at pH 6.0, the liposome membrane would consist of the imidazole-based lipids (C16)/DPPE-PEG 





positively charged imidazole-based lipids and the negatively charged DPPE-PEG.  Based on the 
correlation between liposome stability and the length of acyl chains of lipids, the C16-rich phase 
in ICL would possess less stability compared to the phase of evenly distributed C16 and C18 at 
pH 7.4, therefore the entrapped DOX would leak out faster through the C16 rich phase.  
Based on the results of the drug release study, the addition of cholesterol hindered the 
sensitivity to acidic pH of ICL but enhanced the drug release of ICL at 37℃.  Similar with 
cholesterol’s prohibition of pH-triggered display of positive surface charges, the prohibition of 
pH-triggered drug release can also be explained by cholesterol’s inhibition of the phase 
separation of ICL.  According to the “umbrella model” [199] that is explained in 3.3.1, the 
cholesterol molecules associate with the neighboring phospholipids because of their poor 
polarity, hence hindering the lateral redistribution of the lipids to form separate phases.  
Moreover, the addition of cholesterol to lipid bilayers in gel phase was reported to disrupt the 
original packing of lipids, thus increasing the lateral diffusion coefficient of the bilayers at T < 
Tm [188, 202].  This can explain the enhancement of drug released from ICL with cholesterol 
compared with cholesterol-free ICL at pH 7.4.   
The physical stability of liposomes concerns the maintenance of liposome size against 
aggregation and fusion and the retention of entrapped drug against premature leakage [177].  
Therefore, evaluation of ICL stability needs comprehensive assessment of their size, 
encapsulation efficiency (EE), and drug release.  In our case, EE is determined both by the 
efficiency of the drug loading that is driven by ion gradient and by drug leaking out during the 
drug loading.  Therefore, both size and EE of DOX-loaded liposomes reflects their stability at the 
temperature during drug loading (T ≥Tm).  On the other hand, drug release of ICL indicates their 





cholesterol-free liposomes (ICL and NSL) (Table 3.3), the liposome of better stability at T ≥Tm 
(smaller sizes and higher EE) also showed more stability at 37˚C (slower drug release in 12 
hours at 37˚C).  DHDMI/DSPC/DPPE-PEG showed the highest stability among all the 
cholesterol-free liposomes.  The addition of cholesterol appeared to increase the stability of 
liposomes at T ≥ Tm but decrease their stability at 37˚C.  This is consistent with the prior findings 
that for the bilayers incorporated with cholesterol, their lateral diffusion coefficient is reduced at 
T ≥ Tm due to the decrease of lipid mobility [125, 186], but increased at T < Tm due to the 
disturbance of lattice arrangement [188].  This effect induced the formulations to leak the 
entrapped DOX faster than the cholesterol-free counterparts at 37˚C.   
 
Table 3.3 
Comparison of sizes, EE and DOX release (at pH 7.4 in 12 hours) reflecting stability of 




T ≥Tm 37˚C (T < Tm) 
Lipid Compositions Sizes (nm) EE (%) 
DOX Release 
(%) 
DHI/DSPC/DPPE-PEG 25/70/5 802.7 41.28±0.45 64.53±1.74 
DHMI/DSPC/DPPE-PEG 25/70/5 693.0 52.17±1.52 53.65±2.27 
DHDMI/DSPC/DPPE-PEG 25/70/5 246.1 65.55±0.65 20.36±0.83 
DSPC/DPPE-PEG 95/5 372.7 52.80±0.69 29.56±0.70 
DHI/DSPC/DPPE-PEG/Chol 25/45/5/25 133.6 71.38±0.61 56.19±0.78 
DHMI/DSPC/DPPE-PEG/Chol 25/45/5/25 120.0 89.86±1.27 47.11±0.60 
DHDMI/DSPC/DPPE-PEG/Chol 25/45/5/25 120.7 92.97±1.10 40.32±0.99 
DSPC/DPPE-PEG/Chol 70/5/25 144.1 60.98±1.66 57.70±3.03 
Note. Size values are the cumulative intensity of hydrodynamic diameters. EE and DOX release 







The pH-dependent ζ- potential measurement assays, model liposome-interaction assays, 
and drug release assays were carried out to characterize the pH-sensitivity of ICL with and 
without cholesterol.  The cholesterol-free ICL formulations containing DHI, DHMI or DHDMI 
showed substantial pH-sensitivity by elevation of ζ- potentials and by interaction with model 
liposomes, indicating their conversion in response to acidic pH (pH 6.0-7.0).  The ICL containing 
DHMI also showed low pH-enhanced drug release.  However, the incorporation of cholesterol 
hindered both the pH-triggered display of positive surface charge and the pH-triggered drug 
release of ICL.  
Based on the results of Chapter II and Chapter III, it is found that although incorporation 
of cholesterol seems to be highly effective in improving the sizes and EE of ICL, it has the 
disadvantage of prohibiting the pH-sensitivity.  In comparison, reducing the input DOX 
concentration during drug-loading appears to be a more practical way to decrease the size of ICL 
while maintaining their pH-sensitivity.  ICL of smaller size, higher EE and higher pH-sensitivity 





CHAPTER 4:   MORPHOLOGICAL STUDIES ON IMIDAZOLE-BASED CONVERTIBLE 
LIPOSOMES USING TRANSMISSION ELECTRON MICROSCOPY (TEM) 
 
4.1 Introduction 
Transmission electron microscopy (TEM) is a microscopy technique using a beam of 
electrons to transmit through a specimen to obtain an image.  As the beam transmits through a 
specimen, its electrons interact with the sample to form the image.  Compared with light 
microscopy, TEM is capable of imaging in outstandingly higher resolutions.  The smaller de 
Broglie wavelength [203] of electrons enables the TEM instrument to capture fine morphological 
details, such as structures of nanotubes and virus.  Therefore, TEM finds applications in cancer 
research, virology, nanotechnology and material science.  In conventional TEM, the specimen 
must be either cut into ultrathin sections (< 100 nm thick) or suspended and then coated onto a 
grid [204] to allow the transmission of the electron beam.  Specimen preparation is specific to 
the materials to be analyzed and types of information to be obtained from the images.  The 
samples/sample areas with heavy metals would appear darker and have greater contrast against 
the background while the samples consisting of non-metals would not scatter electrons and thus 
cannot be distinguished from the background.  Hence, such non-metal samples need to be stained 
with a heavy metal stain during specimen preparation [205].  The stain absorbs the passing 
electrons which would otherwise be projected onto the imaging detector.  Solutions/suspensions 
of salts of heavy metals such as osmium, lead, uranium and gold can be used as the stain of TEM 
imaging (7).  TEM samples can be stained with either positive stains that bind to the actual 
specimen and visualize the internal components or negative stains that bind to the background 






In this chapter’s studies, we aimed to utilize TEM techniques to record the morphology of 
ICL at physiological pH 7.4 and acidic pH.  Comparison of the images at different pHs will test 
and monitor ICL’s morphological changes in response to acidic pH.   
4.1.1 Negative staining techniques in TEM.  Negative staining is a technique applied in 
microscopy to contrast a specimen against the background, in which the background is stained, 
and the actual specimen is excluded from the staining.  In the case of TEM, opaqueness to 
electrons is affected by number of protons in the nuclei of the sample.  Commonly used negative 
stains include ammonium molybdate, uranyl acetate (UA), uranyl formate (UF), phosphotungstic 
acid (PTA), osmium tetroxide and osmium ferricyanide [15], owing to their capability to scatter 
electrons and adsorption to biological matter.  Negative staining technique has been applied to 
image virus, bacteria, biological membrane structures and protein, due to their low capacity to 
scatter electrons [207].  Beside biological samples, negative staining has also been employed to 
study lipidic colloids in aqueous media, such as lamellar liposomes and inverted micelles [208].  
Negative staining was reported to lead to flattening of specimen [209, 210].  As shown in Figure 
4.1, a liposome which possesses spherical structure would be flattened but still intact in negative 
stain.   
 
 
Figure 4.1.  Schematic of liposome in solution and flattened intact liposome in negative stain under 
TEM. [211] 
 





4.1.2 Application of TEM in characterization of nanomedicines.  The development of 
microscopic techniques has made the studies on the surface and inner structure of nanocarriers 
more straightforward and attractive [212].  A collection of imaging techniques is available to 
characterize the morphology of liposomes and other nanoparticles, including atomic force 
microscopy, environmental scanning electron microscopy (ESEM), transmission electron 
microscopy (TEM) and confocal laser scanning microscopy.  Evaluation of the morphology of 
nanomedicine is crucial for the development of nanomedicines because in vivo behavior of 
nanomedicines is heavily affected by their physical characteristics, including size, homogeneity, 
surface characteristics and lamellarity [211].  Because of its capacity to visualize single particles 
and even provide information on their inner structure, TEM represents an important method to 
characterize nanoparticles.  Three types of TEM methods – drying, staining and cryogenic TEM 
(cryo-TEM) are commonly used to image nanostructures.  Unlike metal particles which can be 
imaged directly due to their high density and stable structures, nanoparticles composed of soft 
materials need preservation prior to TEM [213].  Cryo-TEM is so far considered the best method 
to visualize the native structure of liposomes, in which an ultrathin film of specimen is quickly 
frozen in liquid ethane or a mixture of liquid ethane and propane to generate vitrified films to be 
imaged under TEM at cryogenic temperatures [214].  Figure 4.2 shows TEM images of DOX-
NP® (Liposomal Encapsulated Doxorubicin) prepared with drying, negative staining and cryo-
TEM methods.  Because cryo-TEM requires advanced equipment and relatively complicated 
procedures, the faster and simpler TEM with negative staining is also a commonly used method 










Figure 4.2. Dox-NP® imaged by commonly used TEM techniques: dried sample without staining 
(a), UA-stained sample after two minutes of drying (b), negative stained sample (UA) (c) and cryo-
TEM (d).  White scale bars represent 200 nm and black scale bars 50 nm. [205] 
 
4.2 Materials and Methods 
4.2.1 Materials.  Carbon-coated copper grids (200 mesh) were purchased from 
Polysciences (US).  Filter paper was purchased from Fisher Scientific (Hampton, NH, US). 
Uranyl acetate (UA) was purchased from Sigma-Aldrich (St Louis, MO, US).  2-[4-(2-
hydroxyethyl)piperazin-1-yl]-ethanesulfonic acid (HEPES) and 2-(N-morpholino)ethanesulfonic 
acid (MES) were purchased from Fisher Scientific (Hampton, NH, US). 
4.2.2 Preparation of ICL samples for TEM characterization.  The morphology of ICL 
formulation was observed on a JEOL-JEM 1230 Electron Microscope (JEOL, Japan).  Two-
hundred mesh carbon-coated copper TEM grids were exposed to glow to discharge before use to 
increase their hydrophilicity.  An aliquot (5 µL) of diluted ICL suspension (approximately 1 mM 
total lipids) was dripped onto the grid to wet its surface for 1 min and then blotted with a filter 
paper to generate a thin film.  The sample film was then wetted five times with 5 µL of the 
negative stain (2% uranyl acetate (UA)) between blotting.  The grid was dried at room 
temperature and then transferred into the electron microscope for imaging at an accelerating 
voltage of 100 kV, with the help of Dr. Fei Guo at the Electron Imaging Facility, Department of 





4.2.3 Preparation of ICL samples at acidic pH.  To characterize the morphological 
changes of liposomes in response to acidic pH with TEM, the pH of ICL suspension was 
adjusted from 7.4 to 6.0.  An aliquot (5 µL) of ICL suspension (approximately 1 mM total lipids) was 
dripped onto the grid and blotted with a filter paper.  A small volume (5 µL) of isotonic MES 
buffer (pH 6.0, 10 mM MES, 140 mM NaCl) was then dripped onto the grid to cover the sample 
film for 5 min and then blotted prior to TEM sample staining.  The TEM sample staining and 
imaging procedures were the same as in 4.2.2.   
4.2.4 Preparation of ICL-model liposome mixtures for TEM characterization.  To 
characterize the interaction between ICL and negatively charged model liposomes under TEM, 
ICL formulations were mixed with model liposomes and TEM of the mixture were taken at pH 
7.4 and 6.0.  An aliquot (5 µL) of ICL suspension (approximately 1 mM total lipids) and 5 µL of 
model liposome suspension (approximately 1 mM total lipids) were mixed and 5 µL of the 
mixture was dripped onto the grid and then blotted with a filter paper.  For TEM of the mixture at 
pH 7.4, the sample on the grid was stained by 2% UA directly after the above procedures.  For 
TEM of the mixture at pH 6.0, 5 µL of isotonic MES buffer (pH 6.0, 10 mM MES, 140 mM 
NaCl) was dripped onto the grid to cover the sample film for 5 min and blotted prior to negative 
staining.  The TEM sample staining and imaging procedures were the same as in 4.2.2.  
4.3 Result and Discussions.  
4.3.1 Morphology of ICL at pH 7.4.  As shown in Figure 4.3 (a-b), the 
DHI/DSPC/DPPE-PEG liposome suspension contained spherical and homogeneous particles 
with 80-150 nm size.  The morphology of DHI liposomes at pH 6.0 (Figure 4.3 (c-d)) appears to 







Figure 4.3. TEM images of DOX-loaded DHI/DSPC/DPPE-PEG at pH 7.4 (a-b) and 6.0 (c-d).  
 
As can be seen in Figure 4.4 (a-b), the DHMI/DSPC/DPPE-PEG showed intact and 
spherical structures at pH 7.4.  At pH 6.0 (Figure 4.4 (c-e)), the liposomes showed much brighter 















(Figure 4.4 Continued) 
 
 
Figure 4.4.  TEM images of DOX-loaded DHI/DSPC/DPPE-PEG at pH 7.4 (a-b) and 6.0 (c-e).   
 
The darker area displayed in TEM images represent contents that are stained more by 
uranyl acetate, while the brighter area represents contents that are stained less with uranyl 
acetate.  It has been known that the negative staining contrasts the specimen by staining the 
background and excluding the specimen, thus the stain should not bind with the specimen 
ideally.  However, in the UA aqueous solution (pH 4.2-4.9), the uranyl species with positive 
charge dominate, thus negatively charged molecules stained particularly well [215].  Uranyl ions 
in were reported to bind specifically to phosphate groups in phospholipids, owing to both 
electrostatic interaction and chemical reaction [216].  In our results, the DHMI/DSPC/DPPE-
PEG liposomes were inadequately contrasted at pH 7.4, but became evidently much brighter at 
pH 6.0, indicating that less UA stain was binding with the liposomes at pH 6.0, which is 
probably because the liposomes converted to cationic liposomes and became exclusive to the 
positively charged UA stain.  This is in line with the pH-triggered acquisition of positive charges 
by ICL confirmed in Chapter III.  Similarly, DHI/DSPC/DPPE-PEG at pH 6.0 turned slightly 
brighter than at pH 7.4, indicating they probably also acquired some positive charges.  In 
addition, the images of the DHMI/DSPC/DPPE-PEG at pH 6.0 also showed some deformed and 






scattered structures (Figure 4.4 (c) and (d)).  These fragmented structures are probably the 
remains of liposomes that had burst and released drug in respond of acidic pH.  
As shown in Figure 4.5 (a-b), the morphology of DHDMI/DSPC/DPPE-PEG appeared to 
have smaller average size compared with the corresponding DHI/DSPC/DPPE-PEG and DHMI 
/DSPC/DPPE-PEG liposomes.  Some DHDMI/DSPC/DPPE-PEG liposomes showed two 
differently stained areas on the surface (Figure 4.5 (b)), which is probably due to the phase 
separation caused by interaction between DHDMI and DPPE-PEG.  Figure 4.5 (c-e) showed 
evident change of morphology of DHDMI/DSPC/DPPE-PEG liposomes in that the liposomes 
were partially turned much brighter showed extremely sharper and clearer boundary of two 
differently stained phases at pH 6.0 compared with pH 7.4. 
 
 








(Figure 4.5 Continued) 
Figure 4.5.  TEM images of DOX-loaded DHDMI/DSPC/DPPE-PEG at pH 7.4 (a-b) and 6.0 (c-
e).  
 
Similar to DHMI/PSPC/DPPE-PEG liposomes, the response of DHDMI/DSPC/DPPE-
PEG liposomes to acidic pH as shown by the TEM images can also be explained by the 
acquisition of positive charges.  The DHDMI/DSPC/DPPE-PEG converted to cationic liposomes 
at pH 6.0 and had less binging with the positively charged UA stain, thus appearing to be 
brighter compared with pH 7.4.  The two differently stained phases on DHDMI/DSPC/DPPE-
PEG indicated different extent of binding with UA.  In response to acidic pH, the clustering of 
protonated DHDMI and negatively charged DPPE-PEG would cause phase separation on the 
liposomes.  The phase without clustered DPPE-PEG would display excess positive charges than 
the phase with clustered DPPE-PEG, thus being stained less by UA than the phase with clustered 
DPPE-PEG.  The sharper and clearer boundary of the two phases on DHDMI/DSPC/DPPE-PEG 
in Figure 4.5 (d) indicated the phase separation of liposomes was enhanced by the acidic pH 6.0.   
Based on the TEM images of cholesterol ICL, the DHI/PSPC/DPPE-PEG, 
DHMI/PSPC/DPPE-PEG and DHDMI/PSPC/DPPE-PEG liposomes appeared to be 
homogeneous vesicles with size of 80-150 nm. The sizes of ICL obtained by DLS (2.3.2) (100-
200 nm) were generally larger than the sizes observed under TEM, which is probably because 
the thickness of the hydrated PEG coating was also counted into the size measurement of ICL by 
DLS. It has been known that the monomer length of PEG (2 kDa) is 0.35 nm [217]. But due to 
the hydrophilicity of PEG, they are known to bind with water molecules to form a hydration 
shell that surrounds the liposome [51]. Such hydrated PEG coating was reported to have 
thickness of 10 nm [218], which can probably explain the gap between the sizes of ICL measured 





As can be seen in Figure 4.6 (a-c), the morphology of DHI/DSPC/DPPE-PEG/Chol is not 
as spherical and homogenized as the cholesterol-free ICLs (such as DHI/DSPC/DPPE-PEG in 
Figure 4.3).  The liposomes containing cholesterol Figure 4.6 (a-c) showed 80-200 nm size, and 
some layered structures can be seen inside of the liposomes.  Figure 4.6 (d-f) showed that the 
liposomes containing cholesterol had some morphological change in response to acidic pH, but it 
didn’t show the pH-triggered brighten particles and phase separation seen in images of 
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4.3.2 Morphology of ICL interacting with model liposomes.  Compared with 
morphology of DHMI/DSPC/DPPE-PEG liposomes (Figure 4.7 (a)), the large membrane 
structures (150-300 nm) surrounded by the small liposomes in Figure 4.7 (b-c), are considered 
model liposomes, while the small liposomes are DHMI liposomes.  At pH 6.0 (Figure 4.7 (d-f)), 
DHMI/DSPC/DPPE-PG liposomes appeared to assemble on the model liposomes, forming 
aggregation at the size of 300-600 nm.  This result implied at acidic pH, the 
DHMI/DSPC/DPPE-PEG liposomes became positively charged to interaction with negatively 
charged model liposomes.  
 
 
Figure 4.7.  TEM images of DOX-loaded DHMI/DSPC/DPPE-PEG at pH 7.4 (a) and DOX-loaded 
DHDMI/DSPC/DPPE-PEG mixed with mode liposomes at pH 7.4 (b-c) and 6.0 (d-f). 
 
d. e. f. 








The morphology of ICL formulations at physiological pH 7.4 and acidic pH 6.0 were 
characterized by TEM in this chapter’s studies.  Signified by TEM images of liposomes at pH 
7.4, cholesterol-free ICL possess spherical and homogeneous morphology, while the addition of 
cholesterol made ICL more heterogeneous in shape (Figure 4.6 (a-c)).  The morphological 
changes of cholesterol-free ICL in response to acidic pH suggested the acquisition of positive 
charges and phase separation, which was consistent with the results of elevated ζ- potentials in 
Chapter III (Figure 3.3) and our previous DSC thermogram report (Figure 3.2).  The pH-
triggered response of ICL containing DHI, DHMI and DHDMI was also in line with their pKa 
(DHI < DHMI < DHDMI) (Table 3.1).  The DHDMI liposomes appeared to show the most 
evident phase separation at acidic pH but also some phase separation at pH 7.4.  The DHMI 
liposomes showed considerable morphological response to acidic pH.  The DHI liposomes 
showed a little change from pH 7.4 to 6.0.  The bursting of ICL containing DHMI in response to 
acidic pH revealed in TEM images was consistent with their pH-triggered drug release (Figure 
3.5 and 3.6).  At acidic pH, the ICL with cholesterol did not show the interaction between the 
lipid components.  The aggregation of ICL with negatively charged model liposomes at pH 6.0 
was imaged by TEM, which further testified the positive electrification of ICL in response to 
acidic pH, which supported the results in Chapter III (Figure 3.4).  Overall, the morphological 






CHAPTER 5:  EVALUATION OF ANTICANCER ACTIVITY OF DOX-LOADED IMIDAZOLE-
BASED CONVERTIBLE LIPOSOMES ON 3D MULTI-CELLULAR SPHEROIDS (MCS)  
 
5.1 Introduction 
2D monolayer cell culture has been widely utilized as in vitro bio-models to test the 
activity of anticancer drugs, but they are not able to mimic the acidic microenvironment of solid 
tumors in vivo.  In previous studies in our group, to evaluate the pH-triggered anticancer activity 
of DOX-ICL in 2D monolayer cell culture, the cells were incubated with the ICL liposomes that 
were diluted in growth media whose pH was adjusted to 6.0, 6.5, 7.0 and 7.4.  The pH-sensitive 
ICL formulations showed increasing cytotoxicity on both HeLa and B16F10 cells as the growth 
media pH was lowered from 7.4 to 6.0 at DOX concentration of 10 μg/mL (Figure 5.1).  By 
contrast, the cytotoxicity of NSL (DSPC/DPPE-PEG) at pH 6.0 showed no significant difference 
from pH 7.4, suggesting that pH-sensitivity of ICL substantially contributed to their anticancer 
activity.  Among the three ICL formulations, the DHDMI liposomes, which interacted the most 
with model liposomes at pH 6.0, showed the most activity, suggesting that more interaction with 
cancer cells by ICL can enhance their cytotoxicity (Figure 3.4 (a)).  
 
 






(Figure 5.1 Continued) 
 
Figure 5.1. Cytotoxicity of free DOX, DOX-loaded liposome and empty liposome against B16-
F10 cells (a) and HeLa cells (b) after 12 hours of incubation. Data presented as mean ± SD, N = 4. 
[129] 
 
As introduced in Chapter I 1.5, 3D multicellular spheroids (MCS) are more representative 
in vitro models of solid tumors than 2D monolayered cells.  Therefore, MCS have been widely 
utilized to study tumor biology and to evaluate bioactivities of drugs.  Owing to lower oxygen 
and nutrient distribution in their core, MCS possess a necrotic core of lower oxygen level, lower 
pH, and similar profile of gene expression compared to solid tumors in vivo [22, 146].  In 
contrast to 2D monolayer cells in culture, 3D MCS carries complex extracellular matrix (ECM) 
composed of structural proteins of great importance to cell survival, proliferation, and migration 
in solid tumors [150, 219].  In previous studies on ICL, the growth media of the 2D monolayer 
cells were extrinsically adjusted to carry low pH.  By contrast, the acidic microenvironment in 
the core of 3D MCS is intrinsically generated, and thus is expected to trigger our pH-sensitive 





ICL formulations as the acidic core of solid tumors would in vivo In contrast to 2D monolayer 
cells, the 3D MCS also impose an additional barrier for drug penetration through multiple layers 
of cancer cells as solid tumors in vivo.  
The studies reported in this chapter aimed to establish 3D MCS of several commonly 
used cancer cells lines and to use them to evaluate the anticancer activity of ICL in comparison 
with NSL and free DOX.  The 3D MCS of HeLa, A549, MDA-MB-231 and MDA-MB-468 cells 
were constructed and characterized to discover suitable conditions for the following anticancer 
studies.  Both the cholesterol-free formulations (with pH-sensitivity) and the formulations with 
cholesterol (with better physicochemical characteristics) were tested on the MCS models in order 
to compare the impact of pH-sensitivity and physicochemical characteristics (size and EE) on the 
anticancer activity.  
5.1.1 Necrotic cores of 3D MCS.  Similar to the avascular regions of solid tumors, cells 
in MCS form three distinct layers, namely the outer layer composed of proliferating cells, the 
middle layer composed of quiescent cells, and the inner core of necrotic cells [22].   
The formation of the three-layer structure is correlated to the insufficient oxygen 
penetration and depends closely on spheroid volume.  It was reported that MCS of 500 µm or 
larger in diameter would assume the three-layer cell organization, which represents the cell 
heterogeneity in solid tumors [143, 144].  The live/dead fluorescence assay is commonly used to 
assess the viability of cells and distribution of the necrotic core in MCS assisted with confocal 
imaging [144].  The necrotic regions in HeLa, A549, MDA-MB-231 and MDA-MB-468 MCS 






Figure 5.2. Confocal images of the distribution of live and dead cells in HeLa (a), A549 (b), MDA-
MB-231 (c) and MDA-MB-468 (d) 3D MCS. Live cells display green fluoresce while dead cells 
red. [220, 221] 
 
5.1.2 pH gradient of 3D MCS.  In contrast to normal cells, cancer cells have higher 
intracellular pH (pHi) and acidic extracellular pH (pHe) [12].  This reversed pH gradient 
contributes to the accelerated growth rate, invasion and migration of cancer cells [13].  Because 
3D MCS possess a hypoxic extracellular environment that is similar to solid tumor, 3D MCS 
also has a gradient of extracellular pH decreasing from the periphery to the core.  Many confocal 
imaging studies have confirmed such a pH gradient inside MCS using pH-dependent fluorescent 
probes.  The measured pH value inside MCS, although verified to be acidic, varies depending on 
cell lines, size, growth rate and culturing conditions.  The pH in outer layer of glioma cell MCS 
was found to be 7.43, while the pH in the central necrotic core was 6.86, based on the ratio of 
SNARF-1 fluorescence at different wavelengths [222].  In a study that measured the pH at the 
surface of cells in MCS and in animal  tumor models of HeLa, M4A4 and NM2C5 cells, the pH 
in the center of MCS was 6.7-6.8, while the pH in the in vivo tumor core was 6.1-6.4 [223].  Our 
previous studies [220, 221] also found the pH gradient in MDA-MB-468 MCS from 7.71 in 
periphery to 6.36 in center, based on the fluorescent confocal images of spheroids treated with 
SNARF-1.  Due to the gap between the intrinsic acidity in MCS and in vivo tumors, pHe of some 





MCS models were further acidified by buffered media at similar pH with pHe in solid tumor 
cores [224-226].  Reduced drug cellular uptake was found in this type of acidified MCS, which 
indicated the lowered pHe (pH 6.0-6.4) in solid tumors was responsible to their limited drug 
uptake.   
In this chapter’s studies, the intrinsic acidic pHe in MCS is expected to trigger ICL 
formulations when they penetrate to the interstitium of MCS.   
5.2 Materials and Methods 
5.2.1 Materials.  The HeLa, A549, MDA-MB-231 and MDA-MB-468 cell lines were 
purchased from ATCC (Manassas, VA, US).  The Dulbecco’s Modification of Eagle’s Medium 
(DMEM) media, Advanced DMEM/F12 media, Trypsin-EDTA, L-Glutamine, fetal bovine serum 
and collagen was purchased from Thermo-Fisher Scientific (Waltham, MA, US).  The RPMI 
1640 media, Penicillin-Streptomycin, 96-well Ultra-low Attachment Round-button microplates, 
96-well Solid White microplates and CellTiter-Glo 3D cell viability assay were purchased from 
VWR (Radnor, PA, US).   
5.2.2 Constructions of 3D MCS Models 
5.2.2.1 Cell culture maintenance.  Cervical cancer cell line HeLa, lung cancer cell line 
A549, and breast cancer cell lines MDA-MB-231 and MDA-MB-468 were cultured to construct 
MCS for the evaluation of anticancer activity.  HeLa cells were maintained in DMEM media 
(with L-glutamine supplement) (Gibco, Carlsbad, CA, US).  A549 cells were maintained in 
RPMI 1640 media (with L-glutamine supplement) (Corning, NY, US).  The DMEM and RPMI 
1640 media were supplemented with 10% fetal bovine serum (Gemimi, West Sacramento, CA) 
and 1% Penicillin-Streptomycin (Corning, NY, US). MDA-MB-231 and MDA-MB-468 cells 





supplemented with 5% fetal bovine serum, 1% Penicillin-Streptomycin and 1% L-glutamine 
(Invitro, San Diego, CA).  All cells were grown in a humidified atmosphere of 5% CO2 in air at 
37°C and passaged at 85% confluence.   
5.2.2.2 Seeding and culturing of MCS. HeLa (~2000 cells/well), A549 (~5000 
cells/well), MDA-MB-231 (~3000 cells/well) and MDA-MB-468 (~2000 cells/well) cells were 
seeded in 96-well Ultra-low Attachment (ULA) round-bottom Microplates (Corning, NY, US) on 
complete growth media containing collagen (Thermo-Fisher Scientific, Waltham, MA, US).  An 
aliquot (100 μL) of cell suspension was added into each well in 96-well plates, and the cell 
concentrations were determined with a Handheld Automated Cell Counter (Millipore, 
Burlington, MA, US).  The cells were centrifuged (Table 5.1) at 7°C to aggregate in the plates. 
Complete growth media (100 L) was added into each well on the second day after seeding.  The 
growth media were partially changed every other day by replacing 100 μL of media in each well 
with 100 μL fresh growth media to maintain a 200 μL/well total media volume. All MCS were 
grown in a humidified atmosphere of 5% CO2 in air at 37°C.   
5.2.2.3 Morphology of MCS. The morphology of 3D MCS was examined on an inverted 
microscope (Keyence, Osaka, Japan), and the size of MCS was measured by BZ-X Analyzer.  
The spheroid volume was calculated using the following formula,  
𝑆𝑝ℎ𝑒𝑟𝑜𝑖𝑑 𝑉𝑜𝑙𝑢𝑚𝑒 =  
1
2
× 𝐿 × 𝑆2 
Where L = the long axis of spheroid, S = the short axis of spheroid. The MCS reaching 500 μm 
in diameter are subjected to drug treatment as a stringent and representative model.   
5.2.2.4 Determination of sensitivity of MCS to anticancer drug DOX.  Cell viability of 
MCS treated by free DOX at incremental concentrations for 72 hours was obtained to determine 





against MCS.  The MCS were treated by free DOX for 72 hours as in 4.2.2.2 and then assayed as 
in 4.2.2.3.  IC50 (μM) of DOX against MCS of each cell line was then determined.   
5.2.3 Cytotoxicity assays on 3D MCS treated with DOX-loaded formulations  
5.2.3.1 Pretreatment of DOX-loaded liposomes.  Before administration to MCS, the 
DOX-loaded liposomal formulations were pretreated to remove the unencapsulated DOX in the 
liposome suspension, which was generated by leakage during sample storage.  The DOX-loaded 
samples stored at 4°C for over 10 days needed the pretreatment before administration to MCS.  
The DOX-loaded liposomes were mixed with the cation-exchange resin Dowex 50WX-4 
(pretreated as in 2.2.2.2) at DOX: resin = 1:60 (w/w) and shaken on an orbital shaker (Thermo 
Fisher Scientific, Waltham, MA) at approximately 100 rpm for 25 min at room temperature.  The 
resin was then removed by filtering the mixture though glass wool in a syringe.  The 
concentration of the payload DOX of pretreated liposomes was then measured as in 2.2.4.   
5.2.3.2 Treatment of 3D MCS with DOX-loaded liposomes.  One hundred microleter or 
more growth media in each well of 96-well ULA microplate containing 200 μL media and MCS 
was replaced with same volume of DOX-loaded liposome or free DOX solutions in complete 
media at incremental concentrations.  The complete media solutions of DOX were prepared by 
diluting water solutions of DOX with complete growth media by 6-10 folds.  The final DOX 
concentration in each well was calculated according to the fold of dilutions.  The incremental 
concentration set was determined referring to IC50 obtained in 4.2.2.4. Each treatment by DOX-
loaded liposomes orfree DOX solutions were quadruplicated.  The MCS were incubated in a 
humidified atmosphere of 5% CO2 in air at 37°C for 72 hours.  
5.2.3.3 Cell viability of 3D MCS after treatment by DOX-loaded liposomes.  After 72-





US) together with 100 μL media from each well and mixed with 100 μL reagent of CellTiter-Glo 
3D cell viability assay (Promega, WI, US) was added to each well.  The microplate was covered 
with foil and shaken on an orbital shaker for 5 min, then incubated for 25 min at room 
temperature.  The luminescence of the above mixture was measured on the Synergy HT 
microplate reader (Biotek, Winooski, VT, US).  The luminescence of MCS treated by growth 
media with no drug/formulation were referred as 100% cell viability.   
5.3 Results and Discussion 
5.3.1 Conditions to construct MCS models.  The effect of collagen and cell seeding 
number on the morphology of MCS was studied to explore the most suitable set of conditions to 
construct MCS models with different cancer cell lines.   
5.3.1.1 The effect of collagen.  Aiming to construct MCS with spherical structures and 
clear edges, collagen was mixed with cells to be seeded in ULA 96-well plates.  A comparison of 
morphology of MDA-MB-468, A549 and HeLa MCS seeded with and without collagen are 
shown in Figure 5.3. The MDA-MB-468 seeded with 1% collagen, A549 seeded with 0.3% 
collagen and HeLa seeded with 0.1% collagen formed spherical solid structures.  The MDA-MB-
468 cells seeded without collagen appeared to be loose and scattered cells (Figure 5.3 (a)).  The 
A549 cells seeded without collagen formed an irregular non-spherical aggregation (Figure 5.3 
(b)), which appears denser than MDA-MB-468 without collagen.  The HeLa cells seeded without 
collagen (Figure 5.3 (c)) formed a solid and spherical structure, but with a rougher edge than the 







Figure 5.3. (a) Morphology of MDA-MB-468 MCS seeded with no collagen (upper, 2000 
cells/well, 9 days) and 1% collagen (lower, 2000 cells/well, 9 days). (b) Morphology of A549 MCS 
seeded with no collagen (upper, 5000 cells/well, 9 days) and 0.3% collagen (lower, 5000 cells/well, 
4 days). (c) Morphology of HeLa MCS seeded with no collagen (upper, 500 cells/well, 10 days) 
and 0.1% collagen (lower, 2000 cells/well, 7 days).  
 
As a component of the extracellular matrix (ECM), collagen is the most prevalently 
utilized embedding material to aggregate cells for the growth of 3D spheroids [224].  The 
concentration of collagen needed for MCS formation changed over different cell lines, probably 
because it served to only complement various levels of the ECM substrates that were generated 
by cancer cells in culture.  Our results show that, without collagen, different types of cancer cells 
could grow into three different types of morphologies – loose cells, irregular aggregated cells, 
and spheroids.  HeLa cells formed spheroids without collagen and spheroids with very smooth 
edges with only 0.1% collagen. Similarly, the results suggested that A549 probably generate 
more substrates than MDA-MB-468.  In comparison, A549 needed the addition of 0.3% collagen 
to form spheroids, while MDA-MB-468 needed 1%.   
5.3.1.2 Cell seeding density. A number of different cell seeding densities were tested to 
find its effect on the construction of MCS.  As shown in Figure 5.4, with incremental seeding 









densities, the MDA-MB-468 MCS had increasing diameters.  The MCS seeded at 5000 and 
10000 cells/well started to have rough edges after cultured for 7-9 days, and subsequently 
became more scattered over time.  The MCS seeded at 2000 cells/well also showed rough edges 
but after a longer period of 15 days. This result indicated as the seeding density getting higher or 
spheroids growing larger, they start to lose the tight, smooth edge.  The MDA-MB-468 MCS 
seeded at 2000 cells/well still had a clear edge after reaching a diameter of 500 μm, which can be 
the most suitable seeding and growing condition for MDA-MB-468 MCS. The scattering of cells 
is also probably due to increase of aggressiveness of cancer cells after being cultured for over 
time due to the hypoxia of the newly formed solid core (darker area in Figure 5.4) in the 
spheroids.    
 
 
Figure 5.4. Morphology of MDA-MB-468 MCS (500, 1000, 2000, 5000, 10000 cells/well) 
seeded with 1% collagen after 5, 7, 9, 11, 13, 15 days in the ULA 96-well microplates.   













As shown in Figure 5.5, for the HeLa cell line, which is likely to generate more ECM 
substrates during the growth of spheroids (Figure 5.3), the increases of seeding density did not 
induce scattering of cells, but induced more irregular edge of spheroids.  Such deformation in 
response to higher seeding density was considered as a critical factor to determine the suitable 




Figure 5.5.  Morphology of HeLa MCS (1000, 2000, 5000 cells/well) seeded with 0.1% collagen 
after 6 days in the ULA 96-well microplates.  
 
Similarly, the suitable conditions to construct MCS ofother cancer cells were selected 
based on the morphology of spheroids.  The conditions to construct HeLa, A549, MDA-MB-231 
and MDA-MB-468 3D MCS are summarized in Table 5.1.  Both the collagen free (500 
cells/well) and 0.1% collagen (2000 cells/well) conditions suitable to form HeLa MCS.  The 
collagen-free HeLa MCS was later used in our cytotoxicity studies.  Typical morphology of the 
~500 μm HeLa, A549, MDA-MB-231 and MDA-MB-468 MCS for anticancer drug treatments 
are shown in Figure 5.6.   
 
Table 5.1 
Conditions to construct 3D MCS models with HeLa, A549, MDA-MB-231 and MDA-MB-468 
cancer cells.   












(Table 5.1 Continued) 
Seeding Density (cells/well) 500 2000 5000 3000 2000 
Collagen (%) 0 0.1 0.3 1 1 
Centrifuge Speed (g) 1000 1000 300 200 200 
Centrifuge Time (min) 15 15 7 15 15 
Estimated time to reach  
500 μm diameter (days) 





Figure 5.6.  Representative morphology of MCS for anticancer drug treatment: HeLa MCS (500 
cells/well, no collagen, 12 days) (a), A549 MCS (5000 cells/well, 0.3% collagen, 5 days) (b), 
MDA-MB-231 MCS (3000 cells/well, 1% collagen, 5 days) (c) and MDA-MB-468 MCS (2000 
cells/well, 1% collagen, 11 days) (d) with diameter of 500 μm in the ULA 96-well microplates.  
 
5.3.1 Inhibition on growth of MCS by DOX.  The constructed 3D MCS models were 
treated with DOX at incremental concentrations to record morphology and cell viability.  As can 
be seen in Figure 5.7, the HeLa MCS exposed to incremental DOX concentration for 72 hours 
showed significant changes in morphology.  As the DOX concentration increased from 0 to 2 
μM, the spheroid became smaller, which signified that DOX inhibited the growth of spheroids.  
As the DOX concentration increased from 2 to 100 μM, the spheroid showed more and more 
rough edges and became looser, which indicated the deformation of of the spheroids.  As the 
DOX concentration increased from 100 to 500 μM, the spheroids showed smaller sizes besides 
more rough edges, which indicated remarkable loss of cells accompanying the deformation of 









Figure 5.7.  Morphology of HeLa MCS before (a) and after (b) treatment by DOX (72 hours 
exposure) at incremental concentrations.  
 
The half maximal inhibitory concentration (IC50) values of free DOX on HeLa, A549, 
MDA-MB-231 and MDA-MB-468 MCS (Table 5.2) were calculated from cell viability results in 
Figure 5.8 using the GraphPad Prism software.  The IC50 values reported the sensitivity of each 
3D MCS model to DOX, which helped determinate the suitable DOX concentration set for the 
cytotoxicity assay of DOX-loaded ICL.  Treatment by free DOX on MCS was also carried out 
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Figure 5.8.  Cell viability of HeLa, A549, MDA-MB-231 and MDA-MB-468 MCS treated with 
free DOX for 72 hrs. Data presented as mean ± SD, N = 4.  
 
Table 5.2 
IC50 of free DOX on HeLa, A549, MDA-MB-231 and MDA-MB-468 3D MCS.  
Cell Line Hela A549 MDA-MB-231 MDA-MB-468 
IC50 (μM) 1.26±0.04 12.59±1.05 1.18±0.29 0.32±0.12 
Note. Data presented as mean ± SD, N = 4. 
 
5.3.2 Cytotoxicity of ICL on 3D MCS.  After treatment by cholesterol-free ICL, NSL 
and free DOX for 72 hours, the cell viability of 3D MCS was recorded.  As shown in Figure 5.9 
(a), the DHI and DHMI liposomes showed better anticancer activity than NSL against HeLa 
MCS, while DHDMI showed similar activity to NSL.  In Figure 5.9 (d), the DHI, DHMI and 
DHDMI liposomes showed better anticancer activity than NSL on MDA-MB-468 MCS, but the 
improvement is not as evident as on HeLa MCS.  On both HeLa and MDA-MB-468 MCS, the 
DHMI liposomes expressed the best anticancer activity and was comparable to free DOX.  As 
can be seen in Figure 5.9 (b), compared with NSL, ICL did not show better activity on A549 
MCS except for DHI at the highest DOX concentration of 100 μM.  In Figure 5.9 (c), ICL 






Figure 5.9.  Cell viability of Hela (a), A549 (b), MDA-MB-231 (c), MDA-MB-468 (d) MCS 
treated with cholesterol-free ICL, NSL and free DOX for 72 hours. Data presented as mean ± SD, 
N = 4.  
 
Figure 5.10 showed the results of cytotoxicity of free DOX, ICL and NSL containing 
25% cholesterol on 3D MCS.  All the ICL formulations showed similar anticancer activity with 







(Figure 5.10 Continued) 
 
Figure 5.10.  Cell viability of Hela, A549, MDA-MB-231 MCS treated with cholesterol-containing 
ICL (25 mol%), cholesterol-containing NSL (25 mol%) and free DOX for 72 hours. Data presented 
as mean ± SD, N = 4. 
 
According to the pH-sensitivity studies (Chapter III), the cholesterol free ICL showed 
pH-sensitivity in terms of displaying positive surface charges and drug release, while the ICL 
containing cholesterol did not show pH-sensitivity.  Our cytotoxicity studies were carried out on 
MCS models, which were confirmed to provide an acidic extracellular microenvironment.  The 
MCS cytotoxicity studies showed that ICL containing cholesterol exerted similar anticancer 
activity with NSL, in contrast to the cholesterol-free ICL, which showed evidently higher 
anticancer activity than NSL on two MCS models.  The cytotoxicity results were consistent with 
the pH-sensitivity, which suggested that the cholesterol-containing ICL lost their anticancer 
activities because the addition of cholesterol suppressed the liposomal pH-sensitivity from the 
imidazole-based lipids.  On the HeLa and MDA-MB-468 MCS, the cholesterol-free ICL with 
DHMI showed the most anticancer activity among the formulations and was comparable with 
free DOX.  The other cholesterol-free ICL containing DHI and DHDMI, even though showed 
upgraded activity compared with NSL, they expressed lower activity compared with free DOX.  
The lower activity of ICL compared with free DOX is probably due to the limited penetration of 





and 5.10, the IC50 values of cholesterol-free ICL, ICL containing cholesterol and free DOX on 
MCS were calculated and are summarized in Table 5.3, which shows noticeable increase of IC50 
of ICL with cholesterol compared with the cholesterol-free ICL.   
 
Table 5.3 
IC50 values of DOX-loaded liposomes and free DOX on HeLa, A549, MDA-MB-231 and MDA-











25/70/5 3.82±1.13*** ~30 1.38±1.31 0.38±0.21** 
DHMI/DSPC/DPPE
-PEG 
25/70/5 2.07±1.13*** ~40 1.77±1.21 0.31±0.15*** 
DHDMI/DSPC/DPP
E-PEG 
25/70/5 9.51±1.15 ~35 1.86±1.24 0.63±0.10** 
DSPC/DPPE-PEG 95/5 11.41±1.28 ~35 2.37±1.29 1.24±0.13 
DHI/DSPC/DPPE-
PEG/Chol 
25/45/5/25 ~10 ~30 5.13±1.46 - 
DHMI/DSPC/DPPE
-PEG/Chol 
25/45/5/25 10.38±1.33 29.07±2.73 3.62±1.17 - 
DHDMI/DSPC/DPP
E-PEG/Chol 
25/45/5/25 ~10 24.06±1.40 3.26±1.18 - 
DSPC/DPPE-
PEG/Chol 
70/5/25 ~10 33.88±1.62 3.98±1.10 - 
Free DOX - 1.26±0.04 12.59±1.05 1.18±0.29 0.32±0.12 
Note.  Data presented as mean ± SD, N = 4. ** p < 0.01, *** p < 0.001 (to the IC50 of 
DSPC/DPPE-PEG) 
 
Among these three ICL that do not contain cholesterol, the ranking of anticancer activity 
against 3D MCS was DHMI > DHI > DHDMI.  According to the pH-sensitivity studies, the 
ranking of acidic pH-triggered cationic conversion is DHDMI > DHMI > DHI, while the ranking 
of acidic pH-triggered drug release is DHMI > DHI > DHDMI. Ranking of their activity on 2D 
monolayered cells, as reported in our previous cytotoxicity studies (Figure 5.1), was precisely in 





to be more consistent with their pH-triggered drug release.  In 2D cell culture at acidic pH, the 
ICL would convert to cationic liposomes and have better interaction with cancer cells, thus 
significantly improved the local concentration of drug on cells.  In 3D MCS models, ICL would 
be triggered by acidic pH after penetrating into the acidic interstitium of MCS, where the 
enhanced local concentration of drug induced by improved liposome-cell interaction might take 
less effect.  In the meantime, the cellular uptake of DOX inside MCS would be more affected by 
the drug release at the acidic interstitial space inside MCS.   
5.4 Summary 
3D MCS models of HeLa, A549, MDA-MB-231 and MDA-MB-468 cell lines were 
successfully constructed under optimized conditions.  The anticancer activity of DOX-loaded 
ICL in comparison with DOX-loaded NSL and free DOX was evaluated with cytotoxicity on 
MCS models.  Based on the IC50 values, the cholesterol-free ICL, especially the DHMI 
liposomes, showed upgraded anticancer activity against MCS compared with NSL.  The addition 
of cholesterol resulted in lower activity of ICL and caused ICL to show similar inhibition trend 
with NSL, which was consistent with the previously reported suppression of ICL pH-sensitivity 
by the addition of cholesterol (Chapter III).  The cholesterol-free ICL were studied in comparison 
with ICL containing cholesterol because the pH-sensitivity of cholesterol-free ICL and the better 
physicochemical characteristics (size and EE) of ICL containing cholesterol were both expected 
to improve the anticancer activity of liposomes on MCS.  Our cytotoxicity studies indicated that 








CHAPTER 6:  SUMMARY 
 
As the second leading cause of death globally, cancer is a major concern for human 
health.  Most cancers form malignant solid tumors, which possess different biological features 
from healthy tissues, including fenestrated vascular walls, hypoxia, necrosis, acidic 
microenvironment, and unique extracellular matrix (ECM). These abnormal features pose 
challenges as well as opportunities for anticancer treatment.  Poorly developed vasculature in 
tumor compared to normal vasculature present unique advantages for nanomedicines over small 
molecule drugs against cancer.  Nanomedicines more easily move from the porous tumor blood 
vessel into tumor interstitium and then accumulate there due to the lack of tumoral lymphatic 
drainage, a phenomenon known as the enhanced permeability and retention (EPR) effect.  
Moreover, the acidic pH in tumor interstitium (pH 6.0-7.0) represents a promising stimulus to 
trigger nanomedicines to promote cellular uptake of the cargo drugs.   
Liposomes are capable nanocarriers of both hydrophilic and hydrophobic agents due to 
the amphiphilicity of their lipid components.  Liposomes are the most commonly used 
nanocarriers and have yielded multiple nanomedicine products in the market by now.  The 
previously reported stealth liposomes coated with PEG have shown enhanced accumulation in 
tumors owing to their prolonged circulation time.  However, the PEG coating also hinders their 
interaction with cancer cells. In order to improve the anticancer activity of stealth liposomes by 
improving their interaction with cancer cells, but without removing their long circulation 
(stealth) property, three  novel, synthetic imidazole-based lipids were introduced to the liposome 
composition to develop the pH-sensitive, imidazole-based convertible liposomes (ICL).  At 
acidic pH, the imidazole-based lipids would protonate to acquire positive charges, thus clustering 





induce phase separation of the bilayer to generate a PEG-free domain, which displays excess 
positive charges and have enhanced interaction with negatively charged cancer cells.  The pH-
sensitivity introduced by the imidazole-based lipids is expected to improve the anticancer 
activity of stealth liposomes.   
The ICL formulations were successfully prepared, characterized, and optimized to have 
small particle sizes (< 200 nm) and sufficient EE (> 40%).  After synthesizing the imidazole-
based lipids DHI, DHMI and DHDMI, ICL were prepared using film hydration, freeze-anneal-
thawing, and extrusion methods. Doxorubicin (DOX) was chosen as the cargo drug to be loaded 
in ICL using the remote loading method with manganese sulfate gradient.  A collection of 
methods was used to improve the physicochemical characteristics of ICL, including reducing 
loading time, incorporating cholesterol, mixing with resin at T ≥ Tm, filtration, and reducing the 
input DOX concentration.  Incorporating cholesterol and reducing the input DOX were found to 
be the most feasible methods to improve the physicochemical properties of ICL by maintaining 
both small size and high EE.   
The ICL formulations were tested on their pH-sensitivity.  ζ- potential change, interaction 
with model liposomes, and drug release of ICL in response to the change of pH (6.0-7.0) were 
assayed to test the pH-sensitivity of ICL with and without cholesterol.  In response to the drop of 
pH, the cholesterol-free ICL raised their ζ- potentials and aggregated with negatively charged 
model liposomes.  The drop of pH also enhanced the drug release from cholesterol-free ICL.  
Among the three ICL formulations, the DHDMI/DSPC/DPPE-PEG showed the most substantial 
pH-triggered conversion to cationic liposomes, while the DHMI/DSPC/DPPE-PEG showed the 
most significant pH-triggered drug release.  However, ICL with cholesterol didn’t show any of 





Transmission electron microscopy (TEM) was used to study the morphology of ICL and 
their interaction with model liposomes at physiological pH 7.4 and acidic pH 6.0. At pH 7.4, the 
cholesterol-free ICL samples showed intact, spherical, and homogeneous vesicles, while the ICL 
with cholesterol showed more heterogeneous in shape.  At pH 6.0, the surface of cholesterol-free 
ICL, especially DHDMI/DSPC/DPPE-PEG, showed evident phase separation. In contrast, the 
ICL with cholesterol did not show phase separation.  TEM also showed that the cholesterol-free 
ICL aggregated with negatively charged model liposomes at pH 6.0 but had no interactions with 
model liposomes at pH 7.4, which demonstrated their pH-triggered conversion into cationic 
liposomes.   
The anticancer activities of ICL formulations were evaluated in MCS in comparison with 
non-sensitive stealth liposomes (NSL).  3D multicellular spheroids (MCS) were chosen to assess 
the anticancer activities of liposomes, because they more closely resemble the biological features 
of solid tumors than 2D cell cultures, including the acidic microenvironment.  The 3D MCS of 
HeLa, A549, MDA-MB-231 and MDA-MB-468 cell lines were successfully constructed by 
exploring the suitable seeding and culturing conditions.  Cytotoxicity assays on 3D MCS were 
carried out to evaluate the anticancer activity of ICL formulations.  According to the IC50 values, 
the cholesterol-free ICL, especially DHMI/DSPC/DPPE-PEG, showed considerably enhanced 
activity on MCS compared to NSL.  However, ICL with cholesterol showed anticancer activities 
that were similar to NSL but lower than cholesterol-free ICL.   
In summary, it was found that pH-sensitivity is successfully introduced to PEGylated, 
stealth liposomes by the incorporation of imidazole-based lipids, and the pH-sensitivity 
correlated with the enhanced anticancer activity of the resultant ICL liposomes.  In the pH-





liposomes and pH-triggered drug release.  Under TEM, the phase separation and bursting of ICL 
appeared to be consistent with their pH-sensitivity.  The IC50 values of ICL formulations against 
3D MCS confirmed that liposomes with the pH-sensitivity from the imidazole-based lipids 
showed improved anticancer activity than the non-sensitive stealth liposomes.  Among the three 
ICL formulations, DHDMI/DSPC/DPPE-PEG showed the most pH-sensitivity in conversion, 
and the best activity against 2D cancer cells (previous studies); DHMI/DSPC/DPPE-PEG 
showed the most pH-sensitivity in drug release as well as the best activity against 3D MCS.  It 
appears that in 3D MCS, which are more like solid tumors in vivo than 2D cells, the triggered 
release of liposomal delivery systems probably plays a more critical role than the enhanced 
interaction with cancer cells.  Moreover, although the incorporation of cholesterol can improve 
the physicochemical characteristics of ICL, it would also suppress the pH-sensitivity of ICL.  
Against 3D MCS, unlike the cholesterol-free ICL, the ICL with cholesterol showed similar 
anticancer activity with the non-sensitive stealth liposomes, indicating that removing the pH-
sensitivity of liposomes would decrease the anticancer activity.  The pH-sensitivity of ICL played 
a more critical role for activities against MCS than good physicochemical characteristics.  In 
conclusion, the pH-sensitivity introduced by the imidazole-based lipids can enhance the anti-
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